
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="939BE807DB0F4BC500004F6C7614761B.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="ijms" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC10572992/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572992/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="International Journal of Molecular Sciences" /><meta name="citation_title" content="Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe" /><meta name="citation_author" content="Rahman Ud Din" /><meta name="citation_author" content="Anan Jiao" /><meta name="citation_author" content="Yinxia Qiu" /><meta name="citation_author" content="Aarmann Anil Mohinani Mohan" /><meta name="citation_author" content="Kei-Ching Yuen" /><meta name="citation_author" content="Hoi-Tung Wong" /><meta name="citation_author" content="Timothy Ming-Hun Wan" /><meta name="citation_author" content="Phoebe On-Yi Wong" /><meta name="citation_author" content="Chun-Fung Sin" /><meta name="citation_publication_date" content="2023/10" /><meta name="citation_issue" content="19" /><meta name="citation_volume" content="24" /><meta name="citation_doi" content="10.3390/ijms241914646" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC10572992/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC10572992/" /><meta name="citation_pmid" content="37834095" /><meta name="DC.Title" content="Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Multidisciplinary Digital Publishing Institute  (MDPI)" /><meta name="DC.Contributor" content="Rahman Ud Din" /><meta name="DC.Contributor" content="Anan Jiao" /><meta name="DC.Contributor" content="Yinxia Qiu" /><meta name="DC.Contributor" content="Aarmann Anil Mohinani Mohan" /><meta name="DC.Contributor" content="Kei-Ching Yuen" /><meta name="DC.Contributor" content="Hoi-Tung Wong" /><meta name="DC.Contributor" content="Timothy Ming-Hun Wan" /><meta name="DC.Contributor" content="Phoebe On-Yi Wong" /><meta name="DC.Contributor" content="Chun-Fung Sin" /><meta name="DC.Date" content="2023 Oct" /><meta name="DC.Identifier" content="10.3390/ijms241914646" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe" /><meta property="og:type" content="article" /><meta property="og:description" content="T lymphoblastic leukemia (T-ALL) is an aggressive haematolymphoid malignancy comprising 15% of acute lymphoblastic leukemia (ALL). Although its prognosis has improved with intensive chemotherapy, the relapse/refractory disease still carries a dismal prognosis. ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572992/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10572992/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Int%20J%20Mol%20Sci%22[journal]" class="navlink">Int J Mol Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10572992
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10572992/pdf/ijms-24-14646.pdf" class="int-view">PDF (7.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10572992/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10572992/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10572992" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="CPag1mvlYQBMPDtPt7MkxtNsuh2QMr5qxEkOJBgbS9ruqc8gO6hXFDPpIqiZm5F3">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F&amp;text=Bortezomib%20Is%20Effective%20in%20the%20Treatment%20of%20T%20Lymphoblastic%20Leukaemia%20by%20Inducing%20DNA%20Damage%2C%20WEE1%20Downregulation%2C%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572992/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37834095/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37834095/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10572992/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22Int%20J%20Mol%20Sci%22[journal]" class="navlink">Int J Mol Sci</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC10572992
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-ijms.png" alt="Logo of ijms" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="http://www.mdpi.com/journal/ijms/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">Int J Mol Sci.</span> 2023 Oct; 24(19): 14646. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2023 Sep 27. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.3390%2Fijms241914646" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3390/ijms241914646</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC10572992</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37834095">37834095</a></div></div></div><h1 class="content-title">Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Din%20RU%5BAuthor%5D">Rahman Ud Din</a>, <span class="fm-role">Methodology</span>, <span class="fm-role">Formal analysis</span>, <span class="fm-role">Data curation</span>, <span class="fm-role">Writing &#x02013; original draft</span>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Jiao%20A%5BAuthor%5D">Anan Jiao</a>, <span class="fm-role">Methodology</span>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Qiu%20Y%5BAuthor%5D">Yinxia Qiu</a>, <span class="fm-role">Methodology</span>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Mohan%20AA%5BAuthor%5D">Aarmann Anil Mohinani Mohan</a>, <span class="fm-role">Methodology</span>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Yuen%20KC%5BAuthor%5D">Kei-Ching Yuen</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wong%20HT%5BAuthor%5D">Hoi-Tung Wong</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wan%20TM%5BAuthor%5D">Timothy Ming-Hun Wan</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Wong%20PO%5BAuthor%5D">Phoebe On-Yi Wong</a>, and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sin%20CF%5BAuthor%5D">Chun-Fung Sin</a><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"></div></div><div class="contrib-group half_rhythm fm-editor">Istv&#x000e1;n Zupk&#x000f3;, <span class="fm-role">Academic Editor</span></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm139965289594800_ai idm139965295790128_ai idm139965296152816_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139965289594800_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139965289594800_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm139965289594800_ai" style="display:none"><div class="fm-affl" id="af1-ijms-24-14646">Department of Pathology, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, China</div><div id="c1-ijms-24-14646"><sup>*</sup>Correspondence: <a href="mailto:dev@null" data-email="kh.ukh.ygolohtap@581fcs" class="oemail">kh.ukh.ygolohtap@581fcs</a>; Tel.: +852-2255-3173; Fax: +852-2817-7565</div></div><div class="fm-article-notes hide half_rhythm" id="idm139965289594800_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2023 Aug 17; Revised 2023 Sep 21; Accepted 2023 Sep 22.</div></div><div class="permissions half_rhythm hide" id="idm139965289594800_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; 2023 by the authors.</div><div class="license half_rhythm">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI" target="_blank">https://creativecommons.org/licenses/by/4.0/</a>).</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div><a href="/pmc/articles/PMC10572992/bin/ijms-24-14646-s001.zip" data-ga-action="click_feat_suppl">ijms-24-14646-s001.zip</a><span style="color:gray"> (2.2M)</span></div><div class="small guid">GUID: 51713A35-295C-48A8-B0BB-C68C01F75550</div></div></dd></dl><dl data-length="84" class="box-data-avail whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-avl-stmnt" data-ga-action="click_feat_toggler" data-ga-label="Data Availability Statement" class="pmctoggle">Data Availability Statement</a></dt><dd id="data-avl-stmnt" style="display: none;"><p>The data used to support the findings of this study are included within the article.</p></dd></dl></div><div id="abstract-a.p.b.p" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.p.b.ptitle">Abstract</h2><!--article-meta--><div><p class="p p-first-last">T lymphoblastic leukemia (T-ALL) is an aggressive haematolymphoid malignancy comprising 15% of acute lymphoblastic leukemia (ALL). Although its prognosis has improved with intensive chemotherapy, the relapse/refractory disease still carries a dismal prognosis. Thus, there is an urgent need to develop novel therapy for T-ALL. Bortezomib, a 26S proteasome inhibitor, is licensed to treat plasma cell myeloma and mantle cell lymphoma. Due to its favorable side effect profile, it is a novel agent of research interest in the treatment of ALL. Despite an increasing number of clinical trials of bortezomib in T-ALL, its detailed mechanistic study in terms of DNA damage, cell cycle, and mitotic catastrophe remains elusive. Moreover, WEE1, a protein kinase overexpressed in ALL and involved in cell-cycle regulation, has been known to be a novel therapeutic target in many cancers. But the role of bortezomib in modulating WEE1 expression in ALL still remains elusive. In this study, we demonstrate the therapeutic efficacy of bortezomib on T-ALL primary samples and cell lines. Our findings reveal that bortezomib treatment induces DNA damage and downregulates WEE1, leading to G2-M cell-cycle progression with damaged DNA. This abnormal mitotic entry induced by bortezomib leads to mitotic catastrophe in T-ALL. In conclusion, our findings dissect the mechanism of action of bortezomib and provide further insights into the use of bortezomib to treat T-ALL. Our findings suggest the possibility of novel combination therapy using proteasome inhibitors together with DNA-damaging agents in the future, which may fill the research gaps and unmet clinical needs in treating ALL.</p></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">acute lymphoblastic leukemia, proteasome inhibitors, bortezomib, DNA damage, WEE1, mitotic catastrophe</span></div></div><div id="sec1-ijms-24-14646" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1-ijms-24-14646title">1. Introduction</h2><p class="p p-first">T lymphoblastic leukemia (T-ALL) is a hematological malignancy arising from clonal mutations of immature T-cells, and it comprises 15% of acute lymphoblastic leukemia (ALL) [<a href="#B1-ijms-24-14646" rid="B1-ijms-24-14646" class=" bibr popnode">1</a>]. Despite the improvement in therapeutic outcomes with intensive chemotherapy, the outcome of relapse/refractory disease is still dismal. Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a distinct subtype of T-ALL with worse treatment outcomes compared with other subtypes of T-ALL with limited therapeutic options available [<a href="#B2-ijms-24-14646" rid="B2-ijms-24-14646" class=" bibr popnode">2</a>,<a href="#B3-ijms-24-14646" rid="B3-ijms-24-14646" class=" bibr popnode">3</a>]. Therefore, there is an urgent need to develop novel therapies to improve the treatment outcome of T-ALL.</p><p>Previously, cell-cycle pathway dysregulation had been one of the main molecular pathogeneses in ALL, and the use of the CDK4/6 inhibitor played an important role against T-ALL [<a href="#B4-ijms-24-14646" rid="B4-ijms-24-14646" class=" bibr popnode">4</a>,<a href="#B5-ijms-24-14646" rid="B5-ijms-24-14646" class=" bibr popnode">5</a>,<a href="#B6-ijms-24-14646" rid="B6-ijms-24-14646" class=" bibr popnode">6</a>,<a href="#B7-ijms-24-14646" rid="B7-ijms-24-14646" class=" bibr popnode">7</a>]. Bortezomib (formerly known as PS-341), a 26S proteasome inhibitor, was discovered by Dr. Julian Adams and his colleague for inhibiting proteasome activity to treat cancer and inflammatory diseases [<a href="#B8-ijms-24-14646" rid="B8-ijms-24-14646" class=" bibr popnode">8</a>]. Later, bortezomib underwent various clinical trials, and it was then licensed by the Food and Drug Administration (FDA) for treating plasma cell myeloma and relapsed mantle cell lymphoma. Subsequently, bortezomib attracted much attention in research on treating various types of cancer due to its excellent therapeutic efficacy and safety profile [<a href="#B9-ijms-24-14646" rid="B9-ijms-24-14646" class=" bibr popnode">9</a>]. Bortezomib has been shown to be effective in treating relapsed/refractory pediatric ALL, with good therapeutic efficacy and safety profiles when combined with chemotherapy in clinical studies, with no significant increase in the risk of grade 3&#x02013;4 hematological toxicities compared with chemotherapy alone [<a href="#B10-ijms-24-14646" rid="B10-ijms-24-14646" class=" bibr popnode">10</a>,<a href="#B11-ijms-24-14646" rid="B11-ijms-24-14646" class=" bibr popnode">11</a>,<a href="#B12-ijms-24-14646" rid="B12-ijms-24-14646" class=" bibr popnode">12</a>]. Despite the proven efficacy of bortezomib in treating ALL from clinical studies, its mechanism of action is unclear. A previous study has shown that bortezomib achieves a therapeutic effect in Ph-positive B-ALL via upregulation of FoXO3 [<a href="#B13-ijms-24-14646" rid="B13-ijms-24-14646" class=" bibr popnode">13</a>]. Bortezomib also exerts a therapeutic effect in T-ALL by inducing apoptosis [<a href="#B10-ijms-24-14646" rid="B10-ijms-24-14646" class=" bibr popnode">10</a>]. In Notch1-mutated T-ALL, bortezomib downregulates transcription factor Sp1 and, thus, suppresses Notch1 activation to exhibit a cytotoxic effect [<a href="#B14-ijms-24-14646" rid="B14-ijms-24-14646" class=" bibr popnode">14</a>]. The modulation of the cell cycle by bortezomib was demonstrated in other hematological malignancies and solid tumors [<a href="#B15-ijms-24-14646" rid="B15-ijms-24-14646" class=" bibr popnode">15</a>,<a href="#B16-ijms-24-14646" rid="B16-ijms-24-14646" class=" bibr popnode">16</a>,<a href="#B17-ijms-24-14646" rid="B17-ijms-24-14646" class=" bibr popnode">17</a>,<a href="#B18-ijms-24-14646" rid="B18-ijms-24-14646" class=" bibr popnode">18</a>]. However, it remains uncertain whether bortezomib causes DNA damage, modulates the cell cycle, or impairs mitosis in T-ALL, and its underlying mechanism has yet to be explored.</p><p class="p p-last">Furthermore, WEE1 is a protein kinase that inactivates CDK1-bound cyclin B and leads to G2/M arrest and the presence of unrepaired damaged DNA [<a href="#B19-ijms-24-14646" rid="B19-ijms-24-14646" class=" bibr popnode">19</a>]. A recent study found that WEE1 was overexpressed in adult ALL and that inhibiting WEE1 could achieve a therapeutic effect [<a href="#B20-ijms-24-14646" rid="B20-ijms-24-14646" class=" bibr popnode">20</a>]. Overexpression of WEE1 has been shown to be associated with poor prognosis in various solid tumors [<a href="#B21-ijms-24-14646" rid="B21-ijms-24-14646" class=" bibr popnode">21</a>,<a href="#B22-ijms-24-14646" rid="B22-ijms-24-14646" class=" bibr popnode">22</a>,<a href="#B23-ijms-24-14646" rid="B23-ijms-24-14646" class=" bibr popnode">23</a>]. Thus, targeting WEE1 is an emerging novel therapeutic approach in the treatment of ALL. However, the effect of bortezomib on WEE1 expression has not been well studied in T-ALL so far. In this study, we show that bortezomib treatment induces DNA damage, WEE1 downregulation, and G2/M progression with unrepaired DNA, resulting in mitotic catastrophe in T-ALL. Our findings provide mechanistic insights into the role of bortezomib in the treatment of T-ALL and may lead to the development of novel therapeutic strategies for treating T-ALL in the future.</p></div><div id="sec2-ijms-24-14646" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2-ijms-24-14646title">2. Results</h2><div id="sec2dot1-ijms-24-14646" class="sec sec-first"><h3 id="sec2dot1-ijms-24-14646title">2.1. Bortezomib Induced Cytotoxicity in T-ALL</h3><p class="p p-first">T-ALL cell lines were treated with different concentrations of bortezomib for 24 and 72 h, and the cell viability and apoptosis were assessed. The result showed that bortezomib induced cytotoxicity in a dose and time-dependent manner. The IC50 values were calculated both for 24 and 72 h treatment, and the IC50 value at 72 h of treatment was mostly around 10 nM (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f001" rid-ob="ob-ijms-24-14646-f001" co-legend-rid="lgnd_ijms-24-14646-f001"><span>Figure 1</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f001" co-legend-rid="lgnd_ijms-24-14646-f001"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f001/" target="figure" rid-figpopup="ijms-24-14646-f001" rid-ob="ob-ijms-24-14646-f001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965289254544"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965289254544"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f001"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f001/" target="figure" rid-figpopup="ijms-24-14646-f001" rid-ob="ob-ijms-24-14646-f001">Figure 1</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) induced cytotoxicity in T Lymphoblastic Leukemia (T-ALL). T-ALL cell lines and primary patient&#x02019;s sample (Patient CSH T-ALL) were cultured and grown to attain the highest percentage of viability. The cells were then treated for 24 and 72 h with different concentrations of BTZ. Figure corresponds to viability of cells obtained through trypan blue staining after treatment with different concentrations of BTZ. The IC50 values were calculated for both 24 and 72-hour treatments. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as mean &#x000b1; standard error of mean (SEM). Altogether, the data suggested that BTZ induced cytotoxicity in T-ALL cell lines and primary patient&#x02019;s sample in dose and time-dependent manner.</p></div></div></div><p class="p p-last">Moreover, the apoptosis induced by bortezomib treatment was assessed by flow cytometric analysis with annexin V/PI double staining. Consistent with our data on cell viability, the percentage of apoptosis was significantly increased in the bortezomib treatment group compared to vehicle control after 24 and 72 h of treatment. The findings showed that bortezomib induced apoptosis in T-ALL (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f002" rid-ob="ob-ijms-24-14646-f002" co-legend-rid="lgnd_ijms-24-14646-f002"><span>Figure 2</span></a>A,B). </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f002" co-legend-rid="lgnd_ijms-24-14646-f002"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f002/" target="figure" rid-figpopup="ijms-24-14646-f002" rid-ob="ob-ijms-24-14646-f002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965290490752"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965290490752"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f002"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f002/" target="figure" rid-figpopup="ijms-24-14646-f002" rid-ob="ob-ijms-24-14646-f002">Figure 2</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) induced apoptosis in T-ALL. T-ALL cell lines (LOUCY, PEER, and CCRF-CEM) and primary patient&#x02019;s sample (Patient CSH T-ALL) were treated for 24 and 72 h with BTZ (8nM), followed by staining with Annexin V-FITC/PI for flow cytometric analysis of apoptosis. (<strong>A</strong>): Representative flow cytometry plots indicating dramatic increase in percentage of apoptosis after treatment. (<strong>B</strong>): Histograms representing the percentage of apoptosis in vehicle control vs. bortezomib-treated T-ALL cell lines and primary patient&#x02019;s sample (Patient CSH T-ALL). The percentages were statistically compared, and significant differences are denoted as ****: <em>p</em> &#x0003c; 0.0001, ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as the mean &#x000b1; standard error of mean (SEM). FITC: Fluorescein Isothiocyanate. PI: Propidium Iodide.</p></div></div></div></div><div id="sec2dot2-ijms-24-14646" class="sec"><h3 id="sec2dot2-ijms-24-14646title">2.2. Bortezomib Induced Cell-Cycle Changes in T-ALL</h3><p class="p p-first-last">To investigate whether bortezomib inhibited cell proliferation by disrupting the cell cycle, we evaluated the cell-cycle distribution in vehicle control and bortezomib-treated T-ALL cell lines for 24 h using various concentrations. The result showed that bortezomib increased the percentage of cells greater than the G2/M phase in a dose-dependent manner while the percentage of G0/G1 phase cells showed a trend of reduction with the increasing dose of bortezomib treatment, though statistical significance was not reached. (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f003/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f003" rid-ob="ob-ijms-24-14646-f003" co-legend-rid="lgnd_ijms-24-14646-f003"><span>Figure 3</span></a>A,B). Together, these findings suggested that bortezomib treatment induced cell-cycle progression beyond the G2/M phase in T-ALL. The phenomenon observed would induce chromosomal instability and abnormal mitotic entry.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f003" co-legend-rid="lgnd_ijms-24-14646-f003"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f003/" target="figure" rid-figpopup="ijms-24-14646-f003" rid-ob="ob-ijms-24-14646-f003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965292019584"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965292019584"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f003"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f003/" target="figure" rid-figpopup="ijms-24-14646-f003" rid-ob="ob-ijms-24-14646-f003">Figure 3</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) Induced Cell-Cycle Disturbance in T-ALL. T-ALL cell lines were cultured and grown to attain the highest percentage of viability. The cells were then treated for 24 h with different concentrations of BTZ, followed by staining with PI, for flow cytometric analysis of cell cycle. (<strong>A</strong>): Representative cell-cycle flow cytometric plots indicating significant increase in percentage of cells greater than G2/M in bortezomib-treated vs. vehicle control group in T-ALL cells. (<strong>B</strong>): Corresponds to the data of statistical analysis indicating significant increase in percentage of cells greater than G2/M in treated vs. control group in T-ALL cells at different doses of BTZ. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as the mean &#x000b1; standard error of mean (SEM). Significant differences are denoted as ****: <em>p</em> &#x0003c; 0.0001, ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01, *: <em>p</em> &#x0003c; 0.05.</p></div></div></div></div><div id="sec2dot3-ijms-24-14646" class="sec"><h3 id="sec2dot3-ijms-24-14646title">2.3. Bortezomib Induced DNA Damage and Downregulation of WEE1 in T-ALL</h3><p class="p p-first">To further explore the reason for the cell-cycle changes after bortezomib treatment, we assessed the expression level of cell-cycle regulators both at transcriptional and translational levels. Our data show that the mRNA level of CDK1 was significantly reduced in LOUCY, while PEER and CCRF-CEM showed no significant change after 24 h of bortezomib treatment. In line with this, LOUCY showed a significant decrease in the mRNA levels of WEE1 and MDM2, while no significant change was observed in mRNA levels of TP53, CDKN1A, and CCNB1 after 24 h treatment of bortezomib (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f004" rid-ob="ob-ijms-24-14646-f004" co-legend-rid="lgnd_ijms-24-14646-f004"><span>Figure 4</span></a>A). Moreover, CCRF-CEM showed a significant decrease in the mRNA level of CCNB1, while there was a significant increase in MDM2, with no change in the levels of WEE1, TP53, and CDKN1A. Similarly, PEER shows a significant increase in the mRNA level of MDM2 and CDKN1A, while no significant change in the level of WEE1, TP53, CDK1, or CCNB1 was observed after 24 h of bortezomib treatment (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f004" rid-ob="ob-ijms-24-14646-f004" co-legend-rid="lgnd_ijms-24-14646-f004"><span>Figure 4</span></a>A).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f004" co-legend-rid="lgnd_ijms-24-14646-f004"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/" target="figure" rid-figpopup="ijms-24-14646-f004" rid-ob="ob-ijms-24-14646-f004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965292495376"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g004.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g004.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965292495376"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f004"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/" target="figure" rid-figpopup="ijms-24-14646-f004" rid-ob="ob-ijms-24-14646-f004">Figure 4</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) changed mRNA and Protein Expression Profile of Cell-Cycle Regulatory Proteins in T-ALL. T-ALL cell lines were cultured and grown to attain the highest percentage of viability. The cells were then treated for 24 h with different concentrations of BTZ, followed by RNA extraction for real-time quantitative PCR analysis and protein extraction for Western blot analysis. (<strong>A</strong>): Shows the mRNA levels of cell-cycle regulatory genes in T-ALL cell lines. (<strong>B</strong>): Corresponds to Western blot expression profile of cell-cycle regulatory proteins. The result shows that BTZ treatment induced downregulation of WEE1 in all T-ALL cell lines we tested. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as the mean &#x000b1; standard error of mean (SEM). Significant differences are denoted as ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01, *: <em>p</em> &#x0003c; 0.05.</p></div></div></div><p>Western blot analysis was performed to further evaluate the changes in cell-cycle regulatory proteins. Our result showed that p21 and p27 were upregulated upon 24 h of bortezomib treatment in all cell lines we tested. The expression of cyclin B1 also increased as well. Moreover, we also observed an increase in p53 levels in all cell lines after bortezomib treatment. In contrast, the expression of CDK1 was reduced upon bortezomib treatment. Interestingly, we find that the expression of WEE1 protein, a regulator of the G2/M checkpoint, was reduced in all cell lines after 24 h of bortezomib treatment, which was in line with our previous data [<a href="#B24-ijms-24-14646" rid="B24-ijms-24-14646" class=" bibr popnode">24</a>] (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f004/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f004" rid-ob="ob-ijms-24-14646-f004" co-legend-rid="lgnd_ijms-24-14646-f004"><span>Figure 4</span></a>B, <a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Supplementary Figure S1</a>). It has been previously reported that proteasome inhibitors induce DNA double-strand break and block DNA repair in non-small cell lung cancer [<a href="#B25-ijms-24-14646" rid="B25-ijms-24-14646" class=" bibr popnode">25</a>]. The above observations made us hypothesize that bortezomib may cause DNA damage with downregulation of WEE1, resulting in G2/M cell-cycle progression, thus allowing for the cell to enter mitosis with damaged DNA.</p><p class="p p-last">To verify the hypothesis of bortezomib-induced DNA damage, we assessed the DNA damage by DNA fragmentation assay (<a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Supplementary Figure S4</a>). Our results show the effect of DNA fragmentation in the bortezomib-treated group when compared with the vehicle control group, which suggested the presence of DNA damage induced by bortezomib (<a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Supplementary Figure S4</a>). To further confirm the important observation of DNA damage induced by bortezomib, we conducted a comet assay. Our data showed a significant increase in the comet tail length and comet DNA percentage in the bortezomib-treated group versus vehicle control, which again confirmed the DNA damage induced by bortezomib in all T-ALL cell lines we tested (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f005/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f005" rid-ob="ob-ijms-24-14646-f005" co-legend-rid="lgnd_ijms-24-14646-f005"><span>Figure 5</span></a>A&#x02013;C). From the above observations, we concluded that bortezomib induced DNA damage and downregulated WEE1, which allowed the cell to have G2/M cell-cycle progression with damaged DNA. Premature mitotic entry has been shown by various studies to cause mitotic catastrophe and subsequent cell death [<a href="#B26-ijms-24-14646" rid="B26-ijms-24-14646" class=" bibr popnode">26</a>]. </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f005" co-legend-rid="lgnd_ijms-24-14646-f005"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f005/" target="figure" rid-figpopup="ijms-24-14646-f005" rid-ob="ob-ijms-24-14646-f005"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965287059600"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g005.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g005.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965287059600"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f005/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f005"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f005/" target="figure" rid-figpopup="ijms-24-14646-f005" rid-ob="ob-ijms-24-14646-f005">Figure 5</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) Treatment Causes DNA Damage in T-ALL. T-ALL cells were cultured and grown to attain the highest percentage of viability. The cells were then treated for 24 h with BTZ at various concentrations (LOUCY (8 nM), PEER (8 nM), CCRF-CEM (12 nM)), and DNA damage was assessed using comet assay. (<strong>A</strong>&#x02013;<strong>C</strong>): Corresponds to Syber gold-stained DNA damage detected by comet assay in T-ALL cells and the statistical analysis showing percentage of DNA damage in treated versus control groups. DMSO was used as a vehicle control (red). Normal control was denoted in blue. The data in BTZ-treated group were individually statistically compared with normal control (blue) and vehicle control (red). The experiments were performed independently three times (<em>n</em> = 3), and each time, 50 cells were analyzed for comet analysis from each group. All the images were captured using 20&#x000d7; objective lens. The data were presented as the mean &#x000b1; standard error of mean (SEM). Significant differences are denoted as ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01, *: <em>p</em> &#x0003c; 0.05.</p></div></div></div></div><div id="sec2dot4-ijms-24-14646" class="sec"><h3 id="sec2dot4-ijms-24-14646title">2.4. Bortezomib Cytotoxicity Was Reduced in WEE1 Overexpressing Cells</h3><p class="p p-first-last">In order to figure out the effect of bortezomib on WEE1 overexpressing cell lines, we successfully transfected the WEE1 recombinant plasmid in CCRF-CEM and PEER cell lines. After confirming the successful transfection and overexpression of the WEE1 plasmid (<a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Supplementary Figures S2, S3, and S5</a>), we treated the cells with different concentrations of bortezomib for 24 and 72 h, and the cell viability and apoptosis were assessed. The result showed that the effect of cytotoxicity and apoptosis of bortezomib were hampered in WEE1 overexpressing cells (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f006/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f006" rid-ob="ob-ijms-24-14646-f006" co-legend-rid="lgnd_ijms-24-14646-f006"><span>Figure 6</span></a> and <a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007" co-legend-rid="lgnd_ijms-24-14646-f007"><span>Figure 7</span></a>A,B). We further calculated the IC50 values for both 24 and 72 h treatment, and in line with our previous observation, the IC50 values of bortezomib were higher in WEE1 overexpressing cells compared to wild-type (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f006/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f006" rid-ob="ob-ijms-24-14646-f006" co-legend-rid="lgnd_ijms-24-14646-f006"><span>Figure 6</span></a>). This observation suggested that WEE1 downregulation was involved in the therapeutic effect of bortezomib treatment in T-ALL.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f006" co-legend-rid="lgnd_ijms-24-14646-f006"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f006/" target="figure" rid-figpopup="ijms-24-14646-f006" rid-ob="ob-ijms-24-14646-f006"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965287055696"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g006.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g006.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g006.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965287055696"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f006/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f006"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f006/" target="figure" rid-figpopup="ijms-24-14646-f006" rid-ob="ob-ijms-24-14646-f006">Figure 6</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) Efficiency Decreases Against WEE1 Overexpressing T-ALL Cells. WEE1 overexpressing cell lines were cultured and then treated with BTZ along with wild-type cell lines for 24 and 72-h. The figure shows a decrease in viability of cells upon treatment with BTZ for 24 and 72 h. The degree of reduction in cell viability was higher in wild-type (red) compared to WEE1-expressing cells (black). Furthermore, the IC50 values for BTZ were calculated and presented in each figure; the result shows reduced IC50 values for wild-type cells compared to WEE1 overexpressing cells both in 24 and 72 h treatment. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as mean &#x000b1; standard error of mean (SEM).</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f007" co-legend-rid="lgnd_ijms-24-14646-f007"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965289411856"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g007a.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g007a.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g007a.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965289411856"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/?report=objectonly">Open in a separate window</a></div><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965288998048"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g007b.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g007b.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g007b.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965288998048"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/?report=objectonly">Open in a separate window</a></div><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965288997104"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g007c.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g007c.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g007c.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965288997104"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f007"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007">Figure 7</a></div><!--caption a7--><div class="caption"><p>Combined Bortezomib (BTZ) and WEE1 inhibitor (AZD) induce apoptosis in T-ALL Cells. T-ALL cells, including wild-type, WEE1 overexpressing cell lines, and primary patient&#x02019;s sample (Patient CSH T-ALL), were treated for 24 h and 72 h with BTZ (4 nM) and AZD (160 nM) alone and in combination, followed by staining with Annexin V-FITC/PI for flow cytometric analysis of apoptosis. (<strong>A</strong>): Representative flow cytometry plots after 24 h treatment, indicating dramatic increase in apoptotic plus pre-apoptotic cells after treatment. (<strong>B</strong>): Representative flow cytometry plots after 72 h treatment, indicating dramatic increase in apoptotic plus pre-apoptotic cells after treatment. (<strong>C</strong>): Histograms representing the percentage of pre-apoptotic and apoptotic cells in control, BTZ, AZD, and combined treated T-ALL cells. The percentages were statistically compared, and significant differences are denoted as ****: <em>p</em> &#x0003c; 0.0001, ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01, *: <em>p</em> &#x0003c; 0.05. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as the mean &#x000b1; standard error of mean (SEM). FITC: Fluorescein Isothiocyanate. PI: Propidium Iodide.</p></div></div></div></div><div id="sec2dot5-ijms-24-14646" class="sec"><h3 id="sec2dot5-ijms-24-14646title">2.5. The Effect of Combine Bortezomib with Adavosertib in Wild-Type and WEE1 Overexpressing T-ALL Cells</h3><p class="p p-first">To further explore the effect of combined treatment of bortezomib and WEE1 inhibitor, we treated the T-ALL cell lines with bortezomib alone and combined with Adavosertib (AZD), a first-in-class selective WEE1 inhibitor. Our findings suggested that the combined treatment of bortezomib and AZD had an antagonistic effect (CI &#x0003e; 1) after 24 h and 72 h of treatment in wild-type T-ALL cell lines including PEER, CCRF-CEM, and LOUCY (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007" co-legend-rid="lgnd_ijms-24-14646-f007"><span>Figure 7</span></a>A,B and <a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Figure S6 and Supplementary Table S2</a>).</p><p class="p p-last">Furthermore, we also treated WEE1 overexpressing cell lines, PEER-WEE1 and CCRF-CEM-WEE1, with bortezomib and AZD alone and in combination for 24 h and 72 h. Our results suggested that the combined treatment of bortezomib and AZD was additive in WEE1 overexpressing cell lines with CI = 1 (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007" co-legend-rid="lgnd_ijms-24-14646-f007"><span>Figure 7</span></a>A,B and <a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Figure S6 and Supplementary Table S2</a>). </p></div><div id="sec2dot6-ijms-24-14646" class="sec"><h3 id="sec2dot6-ijms-24-14646title">2.6. Bortezomib Induced Mitotic Catastrophe in T-ALL</h3><p class="p p-first-last">To further explore whether bortezomib induces premature mitotic entry and subsequent mitotic catastrophe in T-ALL, we used fluorescence microscopy to study the mitotic disturbance. We divided the cells into three groups, i.e., untreated (normal control), DMSO-treated (vehicle control), and bortezomib-treated group. The majority of the cells in the untreated control and DMSO-treated groups show normal mitotic phases. We observed that the bortezomib-treated group exhibited characteristic nuclear features, including nuclear fracture, nuclear bridge formation, micro-nuclei development, and multiple nuclear lobes formation (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f008/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f008" rid-ob="ob-ijms-24-14646-f008" co-legend-rid="lgnd_ijms-24-14646-f008"><span>Figure 8</span></a>A,B). These features have been previously reported in abnormal chromosome assembly in metaphase, abnormal chromosome segregation in anaphase, and incomplete karyokinesis exhibiting mitotic catastrophe in cancer cells [<a href="#B27-ijms-24-14646" rid="B27-ijms-24-14646" class=" bibr popnode">27</a>,<a href="#B28-ijms-24-14646" rid="B28-ijms-24-14646" class=" bibr popnode">28</a>,<a href="#B29-ijms-24-14646" rid="B29-ijms-24-14646" class=" bibr popnode">29</a>,<a href="#B30-ijms-24-14646" rid="B30-ijms-24-14646" class=" bibr popnode">30</a>,<a href="#B31-ijms-24-14646" rid="B31-ijms-24-14646" class=" bibr popnode">31</a>]. The number of mitotically defective cells in the bortezomib-treated group was significantly higher compared to normal control and vehicle control groups (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f008/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f008" rid-ob="ob-ijms-24-14646-f008" co-legend-rid="lgnd_ijms-24-14646-f008"><span>Figure 8</span></a>B). In conclusion, our data showed that bortezomib induced DNA damage and downregulation of WEE1, resulting in premature mitotic entry with damaged DNA, which caused mitotic catastrophe in T-ALL. </p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="ijms-24-14646-f008" co-legend-rid="lgnd_ijms-24-14646-f008"><a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f008/" target="figure" rid-figpopup="ijms-24-14646-f008" rid-ob="ob-ijms-24-14646-f008"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm139965288991296"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=10572992_ijms-24-14646-g008.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is ijms-24-14646-g008.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC10572992/bin/ijms-24-14646-g008.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm139965288991296"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f008/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_ijms-24-14646-f008"><div><a class="figpopup" href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f008/" target="figure" rid-figpopup="ijms-24-14646-f008" rid-ob="ob-ijms-24-14646-f008">Figure 8</a></div><!--caption a7--><div class="caption"><p>Bortezomib (BTZ) Treatment Induce Cell Death in T-ALL via Mitotic Catastrophe. T-ALL cell lines were cultured and grown to attain the highest percentage of viability. The cells were then treated for 24 h with various concentrations of BTZ (PEER and LOUCY 8 nM, CCRF-CEM 16 nM). The nuclei in each group were stained with DAPI, and images were captured by fluorescence microscope using 20&#x000d7; objective lens. Three hundred cells per group were analyzed, and the number of mitotically defective cells (MC) was counted. (<strong>A</strong>): Corresponds to fluorescence microscopy images of DAPI-stained nuclei in each treatment group. White arrows show cells with mitotic defects. (<strong>B</strong>): Corresponds to the statistical analysis of mitotically defective cells in the treated versus normal control and vehicle groups. DMSO was used as a vehicle control. The experiments were performed independently three times (<em>n</em> = 3), and the data were presented as the mean &#x000b1; standard error of mean (SEM). Significant differences are denoted as ****: <em>p</em> &#x0003c; 0.0001. The data suggest that BTZ treatment induces mitotic catastrophe in T-ALL.</p></div></div></div></div><div id="sec2dot7-ijms-24-14646" class="sec sec-last"><h3 id="sec2dot7-ijms-24-14646title">2.7. Efficacy of Bortezomib, WEE1 Inhibitor, and Combined Treatment in Primary Patient&#x02019;s Sample</h3><p class="p p-first-last">To further explore the efficacy of bortezomib and WEE1 inhibitor in the primary patient&#x02019;s sample, we treated the leukemic cells of a patient newly diagnosed with T-ALL with bortezomib for 24 and 72 h. <a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Supplementary Table S1</a> shows the details of the primary patient&#x02019;s sample. Bortezomib showed a reduction in cell viability and increased apoptosis after treatment for 24 and 72 h (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f001/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f001" rid-ob="ob-ijms-24-14646-f001" co-legend-rid="lgnd_ijms-24-14646-f001"><span>Figure 1</span></a> and <a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f002/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f002" rid-ob="ob-ijms-24-14646-f002" co-legend-rid="lgnd_ijms-24-14646-f002"><span>Figure 2</span></a>A,B). The IC50 of bortezomib was well below 10 nM after treatment for 72 h. The sample was also treated with WEE1 inhibitor alone and in combination with bortezomib for 24 h (<a href="/pmc/articles/PMC10572992/figure/ijms-24-14646-f007/" target="figure" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-f007" rid-ob="ob-ijms-24-14646-f007" co-legend-rid="lgnd_ijms-24-14646-f007"><span>Figure 7</span></a>A,B and <a href="#app1-ijms-24-14646" rid="app1-ijms-24-14646" class=" app">Figure S6 and Supplementary Table S2</a>). The findings showed a combination index of 1, i.e., additive effect. </p></div></div><div id="sec3-ijms-24-14646" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3-ijms-24-14646title">3. Discussion</h2><p class="p p-first">Although the treatment of T-ALL has been improved recently with the introduction of intensive chemotherapy and a risk-adapted treatment regimen, it is still a highly lethal disease, especially in relapse/refractory cases [<a href="#B32-ijms-24-14646" rid="B32-ijms-24-14646" class=" bibr popnode">32</a>]. In our study, we showed that bortezomib downregulated WEE1 with subsequent G2/M cell-cycle progression and DNA damage, resulting in mitotic catastrophe. Despite the proven therapeutic efficacy from clinical studies, the mechanism of action of bortezomib in T-ALL is unclear. The findings shielded the light of important mechanistic insights of bortezomib in treating T-ALL, especially in the aspect of cell-cycle modulation, DNA damage, and mitotic catastrophe. </p><p>Bortezomib was shown to suppress NF-kB pathway and trigger apoptosis [<a href="#B14-ijms-24-14646" rid="B14-ijms-24-14646" class=" bibr popnode">14</a>,<a href="#B33-ijms-24-14646" rid="B33-ijms-24-14646" class=" bibr popnode">33</a>]. Hyperactivation of the NOTCH1 signaling pathway modulates the IKK kinase complex, resulting in the activation of NF-kB pathway [<a href="#B34-ijms-24-14646" rid="B34-ijms-24-14646" class=" bibr popnode">34</a>]. It has been shown that bortezomib induced apoptosis, with or without combination with chemotherapy, on NOTCH1-mutated cell lines or patient&#x02019;s leukemic cells via modulation of the NF-&#x003ba;B pathway [<a href="#B10-ijms-24-14646" rid="B10-ijms-24-14646" class=" bibr popnode">10</a>,<a href="#B35-ijms-24-14646" rid="B35-ijms-24-14646" class=" bibr popnode">35</a>,<a href="#B36-ijms-24-14646" rid="B36-ijms-24-14646" class=" bibr popnode">36</a>]. However, in vitro studies and preclinical studies to evaluate the effect of bortezomib on NOTCH1 wild-type T-ALL and underlying mechanisms are lacking. In addition, studies on the aspect of DNA damage and mitotic catastrophe of ALL induced by bortezomib are scarce. The findings of our study somehow filled these research gaps. Our study showed that a single treatment with bortezomib was active against all T-ALL cell lines, including LOUCY, which has an ETP-ALL phenotype with NOTCH1 wild-type status [<a href="#B37-ijms-24-14646" rid="B37-ijms-24-14646" class=" bibr popnode">37</a>]. The IC50 of these cell lines was comparable to that of plasma cell myeloma and mantle cell lymphoma (both around 10 nM) [<a href="#B38-ijms-24-14646" rid="B38-ijms-24-14646" class=" bibr popnode">38</a>,<a href="#B39-ijms-24-14646" rid="B39-ijms-24-14646" class=" bibr popnode">39</a>]. The findings provide insights for developing a novel therapeutic approach to T-ALL. </p><p>In our study, we demonstrated evidence of DNA damage upon bortezomib treatment in T-ALL. It was proposed that the DNA damage-repairing response is regulated by the ubiquitin&#x02013;proteasome system [<a href="#B40-ijms-24-14646" rid="B40-ijms-24-14646" class=" bibr popnode">40</a>]. A previous study showed that bortezomib induced DNA damage via interfering DNA repairing response in neuroendocrine tumors, and the effect of DNA damage was synergized with DNA damaging agent [<a href="#B41-ijms-24-14646" rid="B41-ijms-24-14646" class=" bibr popnode">41</a>]. Similar effects of synergism were observed when combining bortezomib with chemotherapeutic agents or irradiation in solid tumors [<a href="#B25-ijms-24-14646" rid="B25-ijms-24-14646" class=" bibr popnode">25</a>,<a href="#B42-ijms-24-14646" rid="B42-ijms-24-14646" class=" bibr popnode">42</a>]. However, no more studies have shown the effect of DNA damage and its underlying mechanism in T-ALL upon bortezomib treatment. Although our study provided insightful evidence of DNA damage induced by bortezomib in T-ALL, further studies are needed to elucidate the mechanism of DNA damage induced by bortezomib in T-ALL.</p><p>Furthermore, we observed that the protein level of p53 was increased upon the treatment of bortezomib without significant changes at the mRNA level. Although MDM2 is a negative regulator of p53 via transcriptional and post-translational mechanisms [<a href="#B43-ijms-24-14646" rid="B43-ijms-24-14646" class=" bibr popnode">43</a>], we did not observe a consistent trend of reduction in the MDM2 mRNA level. The findings suggested that bortezomib stabilized p53 protein and prevented its degradation. Bortezomib has been shown to prevent proteosome-mediated degradation of p53 and promote apoptosis in breast cancer cells. Moreover, the increase in p53 expression was a direct result of DNA damage observed in bortezomib treatment [<a href="#B44-ijms-24-14646" rid="B44-ijms-24-14646" class=" bibr popnode">44</a>]. However, the effect of apoptosis could be p53-independent since apoptosis was still observed in p53-null breast cancer cells [<a href="#B45-ijms-24-14646" rid="B45-ijms-24-14646" class=" bibr popnode">45</a>]. Upregulation of p53 was also observed in mantle cell lymphoma after treatment with bortezomib. Moreover, an increase in NOXA expression was noted and promoted the release of BAK/BIM with subsequent events of apoptosis in p53-null mantle cell lymphoma cell lines [<a href="#B46-ijms-24-14646" rid="B46-ijms-24-14646" class=" bibr popnode">46</a>]. However, it is uncertain whether bortezomib can induce p53-independent apoptosis in T-ALL. Further studies are required to investigate the role of p53 in bortezomib-induced apoptosis in T-ALL, especially in TP53-mutated ALL. The presence of TP53 mutations carries a poor prognosis, and this mutation commonly presents in relapsed ALL [<a href="#B47-ijms-24-14646" rid="B47-ijms-24-14646" class=" bibr popnode">47</a>]. </p><p>Previous studies showed that bortezomib induced G2/M cell-cycle arrest in neuroblastoma, CD30-positive anaplastic large cell lymphoma, and mantle cell lymphoma [<a href="#B16-ijms-24-14646" rid="B16-ijms-24-14646" class=" bibr popnode">16</a>,<a href="#B48-ijms-24-14646" rid="B48-ijms-24-14646" class=" bibr popnode">48</a>,<a href="#B49-ijms-24-14646" rid="B49-ijms-24-14646" class=" bibr popnode">49</a>]. Furthermore, G2/M cell-cycle arrest associated with aberrant mitosis or mitotic catastrophe was observed in B-cell lymphoma upon bortezomib treatment [<a href="#B50-ijms-24-14646" rid="B50-ijms-24-14646" class=" bibr popnode">50</a>]. The effect on the cell-cycle modulation by bortezomib had not been extensively studied in T-ALL. Bortezomib has been shown to induce G2/M cell-cycle arrest in ALL with KMT2A-rearrangement via upregulation of p27 by increasing CDKN1B transcription [<a href="#B51-ijms-24-14646" rid="B51-ijms-24-14646" class=" bibr popnode">51</a>]. However, studies to evaluate the phenomenon of mitotic catastrophe and the underlying mechanism in T-ALL upon bortezomib treatment are scarce. Here, our study showed that bortezomib did not induce G2/M cell-cycle arrest, but the progression of the cell cycle beyond G2/M was observed, resulting in a mitotic catastrophe. The findings suggested that there was the presence of G2/M cell-cycle progression with damaged DNA leading to mitotic catastrophe. </p><p>Moreover, we observed WEE1 downregulation upon bortezomib treatment. WEE1 kinase is a G2 m cell-cycle regulator and is overexpressed in various cancers, including ALL. This study showed that ALL with overexpression of WEE1 conferred unfavorable prognosis [<a href="#B20-ijms-24-14646" rid="B20-ijms-24-14646" class=" bibr popnode">20</a>]. Bortezomib reduced the WEE1 expression of B-cell lymphoma cell lines [<a href="#B50-ijms-24-14646" rid="B50-ijms-24-14646" class=" bibr popnode">50</a>], while another study found that bortezomib increased the expression level of WEE1 in vascular endothelial cells [<a href="#B32-ijms-24-14646" rid="B32-ijms-24-14646" class=" bibr popnode">32</a>]. L. Liang et al. failed to show the downregulation of WEE1 by bortezomib in plasma cell myeloma [<a href="#B52-ijms-24-14646" rid="B52-ijms-24-14646" class=" bibr popnode">52</a>]. However, the role of bortezomib in the modulation of WEE1 expression in ALL has not been studied so far. Thus, the results from our study provided good evidence of the downregulation of WEE1 by bortezomib in T-ALL. The protein p53 is the main mediator of the G0/G1 cell-cycle checkpoint in the presence of DNA damage. Leukaemic cells harboring TP53 mutation would result in failure of the G0/G1 checkpoint. WEE1 kinase will halt the cell-cycle progression at the G2 checkpoint [<a href="#B19-ijms-24-14646" rid="B19-ijms-24-14646" class=" bibr popnode">19</a>]. Thus, the downregulation of WEE1 in T-ALL induced by bortezomib would promote mitotic entry with damaged DNA, thus causing a mitotic catastrophe. The overexpression of WEE1 attenuated the therapeutic effect of bortezomib, which indicated that WEE1 downregulation partly contributed to the therapeutic effect of bortezomib. The inhibition of WEE1 could induce cell death via a p53-independent mechanism by modulating the G2 cell-cycle checkpoint, and, therefore, it is an effective treatment strategy for TP53-mutated ALL. Indeed, apoptosis was observed in TP53-mutated leukemic cells via WEE1 inhibition. Combined WEE1 inhibitor (MK1775) and conventional chemotherapy had a synergistic effect in TP53 mutated acute myeloid leukemia [<a href="#B53-ijms-24-14646" rid="B53-ijms-24-14646" class=" bibr popnode">53</a>]. Moreover, this study showed that the synergism of the WEE1 inhibitor (AZD-1775) and clofarabine was due to the potentiation of DNA damage [<a href="#B20-ijms-24-14646" rid="B20-ijms-24-14646" class=" bibr popnode">20</a>]. A recent study also showed that combined bortezomib and WEE1 inhibitor (MK1775) achieved a synergistic effect in multiple myeloma and depleting stem-like cells in multiple myeloma [<a href="#B52-ijms-24-14646" rid="B52-ijms-24-14646" class=" bibr popnode">52</a>]. However, our results did not show a synergistic effect of combined bortezomib and WEE1 inhibitor in both wild-type and WEE1-overexpressing cells, although the combination index in WEE1-overexpressing cells was smaller. We are not sure about the reason behind the antagonism observed in WEE1 wild-type cell lines. However, since WEE1 downregulation at least contributed partly to the therapeutic effect of bortezomib in ALL, the WEE1 inhibition in ALL cells with low-level expression of WEE1 may greatly diminish the effect of WEE1 downregulation by bortezomib and, hence, jeopardize the therapeutic effect of bortezomib. Further studies would be warranted for studying the efficacy of combination with other genotoxic agents, which would potentiate the DNA damage. Further studies are also needed to elucidate the mechanism of WEE1 downregulation in T-ALL upon bortezomib treatment. </p><p>Our study shows the downregulation of CDK 1 and upregulation of cyclin B1 in T-ALL cell lines upon bortezomib treatment. This study showed that bortezomib had a similar effect on CDK1 and cyclin B1 in non-small cell lung carcinoma cell lines [<a href="#B18-ijms-24-14646" rid="B18-ijms-24-14646" class=" bibr popnode">18</a>]. Another study showed that bortezomib increased cyclin B levels in NK/T-cell lymphoma. Moreover, despite the total CDK1 being reduced, the CDK1/Cyclin B activity was increased by increasing phosphorylation at CDK1 upon bortezomib treatment, thus resulting in a mitotic catastrophe [<a href="#B54-ijms-24-14646" rid="B54-ijms-24-14646" class=" bibr popnode">54</a>]. In our study, the observation of upregulation of cyclin B explained the phenomenon of G2/M cell-cycle progression. However, the exact changes in CDK1/Cyclin B activity upon bortezomib treatment in T-ALL, besides the protein expression level, need further investigation.</p><p>Our study showed that the expression of p21 and p27 increased after treatment of bortezomib. Previous work has demonstrated that bortezomib stabilizes p27, p53, and p21 protein with G2/M arrest [<a href="#B17-ijms-24-14646" rid="B17-ijms-24-14646" class=" bibr popnode">17</a>,<a href="#B55-ijms-24-14646" rid="B55-ijms-24-14646" class=" bibr popnode">55</a>,<a href="#B56-ijms-24-14646" rid="B56-ijms-24-14646" class=" bibr popnode">56</a>,<a href="#B57-ijms-24-14646" rid="B57-ijms-24-14646" class=" bibr popnode">57</a>]. In the presence of DNA damage, p21 is responsible for inhibiting the cycling B-CDK1 complex, resulting in G2 cell-cycle arrest [<a href="#B58-ijms-24-14646" rid="B58-ijms-24-14646" class=" bibr popnode">58</a>,<a href="#B59-ijms-24-14646" rid="B59-ijms-24-14646" class=" bibr popnode">59</a>]. P27 is also responsible for inhibiting CDK1 and subsequently leads to G2/M cell-cycle arrest [<a href="#B60-ijms-24-14646" rid="B60-ijms-24-14646" class=" bibr popnode">60</a>]. Therefore, the increase in levels of p21 and p27 may cause G2 cell-cycle arrest. However, we failed to observe G2/M cell-cycle arrest but cell-cycle progression beyond G2/M instead. It is uncertain how the effect of G2/M cell-cycle progression via WEE1 inhibition interacts with the effect of elevated p21 and p27 upon bortezomib treatment. Further mechanistic study on cell-cycle modulation by bortezomib is needed.</p><p class="p p-last">In conclusion, our study showed DNA damage, WEE1 downregulation, and mitotic catastrophe induced by bortezomib treatment in T-ALL. This provides a mechanistic exploration of bortezomib action in T-ALL, especially NOTCH1 wild-type T-ALL. We also showed that bortezomib acts through a novel therapeutic target in the treatment of ALL, WEE1 kinase. Further studies are needed to evaluate the mechanism of WEE1 downregulation. Also, further studies need to explore optimal combination therapeutic strategies, especially combined with other DNA-damaging agents. Finally, our data provide opportunities for further research about the use of proteasome inhibitors to treat T-ALL and improve its prognosis.</p></div><div id="sec4-ijms-24-14646" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4-ijms-24-14646title">4. Materials and Methods</h2><div id="sec4dot1-ijms-24-14646" class="sec sec-first"><h3 id="sec4dot1-ijms-24-14646title">4.1. Drugs, Cytokines, and Antibodies</h3><p class="p p-first">Bortezomib (BTZ) was purchased from Merck. For the in vitro experiments, a 10 mM stock solution was prepared by dissolving it in dimethyl sulfoxide (DMSO) purchased from Sigma-Aldrich. The concentration of DMSO in the culture was kept from 0.1 to 0.2%. The stock solution was stored at &#x02212;20 &#x000b0;C until use. The antibodies for the immunoblots, including GAPDH (14C10), P21<sup>waf1/cip1</sup> (12D1), P53, P27<sup>kip1</sup> (D69C12), CDK1 (POH1), CYCLIN B1 (D5C10), and WEE1 (D10D2), were purchased from Cell Signaling (Beverly, MA, USA), while Anti-DDK(FLAG) (TA50011-100) was purchased from OriGene Technologies, Inc. (Rockville, MD 20850, USA).</p><p class="p p-last">Five cytokines&#x02014;IL-3, IL-6, SCF, G-CSF, and Flt3-L&#x02014;were purchased from PEPRO Tech (Rocky Hill, NJ, USA).</p></div><div id="sec4dot2-ijms-24-14646" class="sec"><h3 id="sec4dot2-ijms-24-14646title">4.2. Cell Lines and Cell Culture</h3><p class="p p-first-last">The human T-ALL cell lines, namely, LOUCY, PEER, and CCRF-CEM were purchased from Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) and authenticated. They were cultured in RPMI-1640 (Invitrogen, Waltham, MA, USA) medium supplemented with 10&#x02013;20% bovine serum (Hyclone, Logan, UT, USA) and 1% penicillin (100 U/mL)/streptomycin (100 ug/mL) (Gibco, Billings, MT, USA). All cultures were maintained at 37 &#x000b0;C in a humidifier atmosphere containing 5% CO<sub>2</sub>.</p></div><div id="sec4dot3-ijms-24-14646" class="sec"><h3 id="sec4dot3-ijms-24-14646title">4.3. Primary Patient Sample</h3><p class="p p-first-last">A primary patient sample with T-ALL was obtained from bone marrow aspiration of the patient with newly diagnosed T-ALL after obtaining informed consent. The experiment was approved by the Institutional Review Board of HKU/HA HKW (Protocol Number: UW19-809). The marrow blood mononuclear cells (MBMC) were extracted using Ficoll Paque Plus (GE17-1440-02) purchased from MERCK (Darmstadt, Germany). The MBMC were cultured in IMDM + GlutaMAX&#x02122; (Gibco Catalog number: 31980030) medium supplemented with 5% fetal bovine serum (FBS), 1% Penicillin-Streptomycin (10,000 U/mL Catalog number: 15140122), and five cytokines (20 nanomole IL-3, 20 nanomole IL-6, 100 nanomole SCF, 20 nanomole G-CSF and 100 nanomole Flt3-L). </p></div><div id="sec4dot4-ijms-24-14646" class="sec"><h3 id="sec4dot4-ijms-24-14646title">4.4. Flow Cytometric Analysis of Apoptosis</h3><p class="p p-first-last">Cells were seeded in the 24-well plates at 0.75 &#x000d7; 10<sup>6</sup> cells/mL with vehicle control and various doses of bortezomib for a duration of 24 h and 72 h. The cells obtained from the treatment were washed with ice-cold phosphate-buffered saline (PBS) after trypsinization and resuspended in the Annexin V binding buffer containing 10 mM Hepes/NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl<sub>2</sub>. These solutions were mixed to make the total density of the solution equal to 0.75 &#x000d7; 10<sup>6</sup> cells/mL. Then, 80 &#x003bc;L of the cell solution was mixed with 10 &#x003bc;L of Annexin V FITC (Pharmingen, San Diego, CA, USA), 10 &#x003bc;L of propidium iodide (50 &#x003bc;g /mL in PBS (pH 7.4), and 0.2 &#x003bc;m sterile-filtered). The frequency of apoptotic cells (Annexin V/PI positive cells) was determined by using a minimum of 10,000 events using the FACS Fortress flow cytometer (Becton Dickinson, Lincoln Park, NU, USA). The data of the flow cytometric study were analyzed by using FlowJo_v10.8.1.</p></div><div id="sec4dot5-ijms-24-14646" class="sec"><h3 id="sec4dot5-ijms-24-14646title">4.5. Flow Cytometric Analysis of Cell Cycle</h3><p class="p p-first-last">Cells were seeded at a density of 1 &#x000d7; 10<sup>6</sup> cells/well in a 24-well plate treated with vehicle control and various doses of bortezomib, then harvested after 24 h with washing by PBS before being fixed and permeabilized with 2% PFA at 4 &#x000b0;C overnight. The cells were incubated with RNase and propidium iodide. The data were acquired with a FACS Fortressa flow cytometer (Becton Dickinson, Lincoln Park, NJ, USA). FlowJo_v10.8.1 software was used to calculate the proportion of cells in different phases. </p></div><div id="sec4dot6-ijms-24-14646" class="sec"><h3 id="sec4dot6-ijms-24-14646title">4.6. Trypan Blue Staining Assay</h3><p class="p p-first">The 0.4% Trypan Blue staining solution assay (Thermo Fisher-Scientific, Waltham, USA) can differentiate between live and dead cells by the dye exclusion test. It is an impermeable dye to viable cell membranes, which freely permeates into apoptotic cells. For this procedure, a 1:2 dilution of cell culture was mixed with 0.4% trypan blue stain (10 &#x003bc;L of cell culture was added to 10 &#x003bc;L of trypan blue). A total of 10 &#x003bc;L of the mixture was then loaded onto a TC20 counting slide, which was then inserted into the TC20 automated cell counter (Bio-Rad Inc., Hercules, California), where it was automatically counted.
</p><div class="disp-formula"><div class="f">Viability (%) = viable cell count / total cell count &#x000d7; 100</div></div><p></p><p class="p p-last">The viability of the vehicle control and bortezomib-treated cell culture was analyzed in this study.</p></div><div id="sec4dot7-ijms-24-14646" class="sec"><h3 id="sec4dot7-ijms-24-14646title">4.7. Immunoblot Analysis</h3><p class="p p-first-last">After treatment of the leukemia cells with vehicle control and bortezomib for 24 h, the cells were lysed with RIPA buffer, and the cell lysate samples (50 &#x003bc;g/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 8&#x02013;12% gels. After separation of proteins, they were transferred to a polyvinylidene difluoride (PVDF) membrane and subsequently blocked with 5% (<em>v/v</em>) non-fat dried milk prepared in Tris-buffered saline containing 0.1% tween-20 and incubated with corresponding antibodies at 1:1000 and secondary antibodies at 1:1000. The immunoreactive protein bands were visualized using Alliance Q9 Advanced Chemiluminescence Imager (Uvitec, Cambridge, UK). The expression of p21, p53, p27, CDK1, cyclin B1, and WEE1 were studied via Western blot.</p></div><div id="sec4dot8-ijms-24-14646" class="sec"><h3 id="sec4dot8-ijms-24-14646title">4.8. Quantitative RT-PCR Study</h3><p class="p p-first-last">Quantitative RT-PCR was performed on cells treated with vehicle control and bortezomib for 24 h. Total RNA was extracted and purified using a mirVana miRNA isolation kit (Thermofisher Scientific, Wilmington, DE, USA). The concentration and quality were measured using nanodrop ND1000 (Thermofisher Scientific, DE, USA) by spectrophotometric determination. A criterion using the 260/280 ratio being over 1.8 was used to determine whether the RNA quality was pure enough to continue to reverse transcription. The RNA was reversed transcribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit according to the manufacturer&#x02019;s instructions. Primers were designed (<a href="/pmc/articles/PMC10572992/table/ijms-24-14646-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="ijms-24-14646-t001" rid-ob="ob-ijms-24-14646-t001" co-legend-rid=""><span>Table 1</span></a>), and qPCR was conducted. The conditions were set to pre-denaturation at 95 &#x000b0;C for 25 s, 40 cycles of amplification with denaturation at 95 &#x000b0;C for 15 s, annealing at 60 &#x000b0;C for 60 s, and extension at 72 &#x000b0;C for 30 s. GAPDH was used as a housekeeping gene to normalize the data.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="ijms-24-14646-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><p>Forward and Reverse Primers Used in RT-qPCR.</p></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Forward Sequence</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reverse Sequence</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">GAPDH</td><td align="left" valign="middle" rowspan="1" colspan="1">GTCTCCTCTGACTTCAACAGCG</td><td align="left" valign="middle" rowspan="1" colspan="1">ACCACCCTGTTGCTGTAGCCAA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDK1</td><td align="left" valign="middle" rowspan="1" colspan="1">GGAAACCAGGAAGCCTAGCATC</td><td align="left" valign="middle" rowspan="1" colspan="1">GGATGATTCAGTGCCATTTTGCC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WEE1</td><td align="left" valign="middle" rowspan="1" colspan="1">GATGTGCGACAGACTCCTCAAG</td><td align="left" valign="middle" rowspan="1" colspan="1">CTGGCTTCCATGTCTTCACCAC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TP53</td><td align="left" valign="middle" rowspan="1" colspan="1">CCTCAGCATCTTATCCGAGTGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TGGATGGTGGTACAGTCAGAGC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDKN1A</td><td align="left" valign="middle" rowspan="1" colspan="1">AGGTGGACCTGGAGACTCTCAG</td><td align="left" valign="middle" rowspan="1" colspan="1">TCCTCTTGGAGAAGATCAGCCG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCNB1</td><td align="left" valign="middle" rowspan="1" colspan="1">GACCTGTGTCAGGCTTTCTCTG</td><td align="left" valign="middle" rowspan="1" colspan="1">GGTATTTTGGTCTGACTGCTTGC</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDM2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGTTTGGCGTGCCAAGCTTCTC</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CACAGATGTACCTGAGTCCGATG</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm139965334092048"><a target="object" rel="noopener" href="/pmc/articles/PMC10572992/table/ijms-24-14646-t001/?report=objectonly">Open in a separate window</a></div></div></div><div id="sec4dot9-ijms-24-14646" class="sec"><h3 id="sec4dot9-ijms-24-14646title">4.9. WEE1 Plasmid and WEE1 Inhibitor</h3><p class="p p-first-last">For generating WEE1 overexpressing cell lines, WEE1 (<a id="__tag_1141569201" class="tag_hotlink" href="/nuccore/NM_003390" ref="/nuccore/NM_003390"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"NM_003390","term_id":"1519241777","term_text":"NM_003390"}}</span>NM_003390</a>) Human Tagged ORF Clone (RC209760), purchased from OriGENE (Rockville, MD 20850, USA), was transfected to T-ALL cell lines using Lipofectamine 3000 Transfection Reagent (ThermoFisher) according to the instruction of package insert. WEE1 inhibitor, Adavosertib (Synonyms: AZD1775; MK-1775), was purchased from MCE (Hong Kong).</p></div><div id="sec4dot10-ijms-24-14646" class="sec"><h3 id="sec4dot10-ijms-24-14646title">4.10. Agarose DNA Gel Electrophoresis</h3><p class="p p-first-last">Cells were seeded in a 6-well plate at a density of 1.5 &#x000d7; 10<sup>6</sup> per mL. A total of 4.5 &#x000d7; 10<sup>6</sup> cells were seeded per well and treated with different bortezomib concentrations for 24 h. After treatment, the cells were harvested, and genomic DNA was extracted according to the package insert of DNeasy Blood and Tissue Kit QIAGEN (Cat. No. 69504). The recovered DNA concentration was measured using Nanodrop. The DNA fragmentation was analyzed by 1% Agarose Gel electrophoresis using a Bio-Rad system (Voltage 180, Time 1:15 h). Gel was visualized using Gel-Doc XR plus system (Bio-Rad) and documented.</p></div><div id="sec4dot11-ijms-24-14646" class="sec"><h3 id="sec4dot11-ijms-24-14646title">4.11. Comet Assay for Measuring DNA Damage</h3><p class="p p-first-last">CometAssay<sup>&#x000ae;</sup> Reagent Kit for a Single Cell Gel Electrophoresis Assay Catalog # 4250-050-K was purchased from R&#x00026;D systems, and the reagents were made according to the manufacturer&#x02019;s instructions. The alkaline comet assay was performed on cells treated with vehicle control and bortezomib after treatment for 24 h, according to the manufacturer&#x02019;s instructions. The comet images were taken using a fluorescence microscope (Nikon Live Cell Imaging System). A total of 50 cells per treatment were analyzed, the comet tail length and tail percent DNA were calculated, and the mean value was determined. The images were processed by the automatic comet assay software CometScore Pro 2.0 (2012 TriTek Corp). </p></div><div id="sec4dot12-ijms-24-14646" class="sec"><h3 id="sec4dot12-ijms-24-14646title">4.12. Mitotic Study</h3><p class="p p-first-last">The mitotic disturbance induced by bortezomib treatment was studied in T-ALL cell lines after treatment with vehicle control and bortezomib for 24 h by using the previously published protocol with few modifications [<a href="#B61-ijms-24-14646" rid="B61-ijms-24-14646" class=" bibr popnode">61</a>]. The cells were seeded in a density of 0.3 &#x000d7; 10<sup>6</sup> cells/mL (CCRF-CEM) or 1 &#x000d7; 10<sup>6</sup> cells/mL (PEER and LOUCY) and treated for 24 h along with the vehicle control. For PEER and LOUCY, the plates were coated with Poly-L-Lysine (0.1% <em>w/v</em>, Catalog No. P 8920, SIGMA-ALDRICH CO) prior to seeding the cells. The images of DAPI-stained nuclei were taken using a fluorescence microscope (Nikon Live Cell Imaging System) and were processed using ImageJ software 1.53t. A total of 300 cells from each group were analyzed, and the number of nuclei exhibiting the mitotic catastrophe was counted. </p></div><div id="sec4dot13-ijms-24-14646" class="sec sec-last"><h3 id="sec4dot13-ijms-24-14646title">4.13. Statistical Analysis</h3><p class="p p-first-last">All the experiments were performed three times independently (<em>n</em> = 3). The data are expressed as mean &#x000b1; standard error of the mean (S.E.M.). The difference in data among groups was calculated by one-way analysis of variance (ANOVA) and post hoc Tukey&#x02019;s test as appropriate. The difference between groups was determined by the Student&#x02019;s <em>t</em>-test. All statistical analyses were performed using GraphPad Prism 9 (GraphPad Software Inc., La Jolla, CA, USA). A <em>p</em>-value of lower than 0.05 was taken as statistically significant. Significant differences are denoted as ***: <em>p</em> &#x0003c; 0.001, **: <em>p</em> &#x0003c; 0.01, *: <em>p</em> &#x0003c; 0.05.</p></div></div><div id="app1-ijms-24-14646" class="tsec sec"><h2 class="head no_bottom_margin" id="app1-ijms-24-14646title">Supplementary Materials</h2><!--/article/back/app-group/app/--><p>The following supporting information can be downloaded at <a href="https://www.mdpi.com/article/10.3390/ijms241914646/s1">https://www.mdpi.com/article/10.3390/ijms241914646/s1</a>.</p><div class="sec suppmat" id="ijms-24-14646-s001"><div class="sup-box half_rhythm" id="media-a.r.b.a.c.a"><a href="/pmc/articles/PMC10572992/bin/ijms-24-14646-s001.zip" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(2.2M, zip)</sup></div></div></div><div id="funding-group-a.p.b.r" class="tsec sec"><h2 class="head no_bottom_margin" id="funding-group-a.p.b.rtitle">Funding Statement</h2><p>This research was funded by Health and Medical Research Fund of Health Bureau with grant number 07182526.</p></div><div id="notes-a.r.c" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.ctitle">Author Contributions</h2><p>Conceptualization, C.-F.S. and R.U.D.; methodology, C.-F.S., R.U.D. and T.M.-H.W.; formal analysis, R.U.D.; investigation, C.-F.S. and R.U.D.; resources, C.-F.S.; data curation, R.U.D., A.J., Y.Q., A.A.M.M., K.-C.Y., H.-T.W., T.M.-H.W. and P.O.-Y.W.; writing&#x02014;original draft preparation, R.U.D.; writing&#x02014;review and editing, C.-F.S.; visualization, R.U.D., A.J., Y.Q., A.A.M.M., K.-C.Y., H.-T.W., T.M.-H.W. and P.O.-Y.W.; supervision, C.-F.S.; project administration, C.-F.S.; funding acquisition, C.-F.S. All authors have read and agreed to the published version of the manuscript.</p></div><div id="notes-a.r.d" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.dtitle">Institutional Review Board Statement</h2><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB) with protocol number UW19-809. The approval date was 16 December 2019.</p></div><div id="notes-a.r.e" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.etitle">Informed Consent Statement</h2><p>Informed consent was obtained from all subjects involved in the study.</p></div><div id="notes-a.r.f" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.ftitle">Data Availability Statement</h2><p>The data used to support the findings of this study are included within the article.</p></div><div id="notes-a.r.g" class="tsec sec"><h2 class="head no_bottom_margin" id="notes-a.r.gtitle">Conflicts of Interest</h2><p>The authors declare no conflict of interest.</p></div><div id="fn-group-a.r.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.r.atitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.r.a.a"><p class="p p-first-last"><strong>Disclaimer/Publisher&#x02019;s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></p></div></div><div id="ref-list-a.r.h" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.r.htitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1-ijms-24-14646">1. <span class="element-citation">Vadillo E., Dorantes-Acosta E., Pelayo R., Schnoor M. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. <span><span class="ref-journal">Blood Rev. </span>2018;<span class="ref-vol">32</span>:36–51. doi: 10.1016/j.blre.2017.08.006.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28830639" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.blre.2017.08.006" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood+Rev.&amp;title=T+cell+acute+lymphoblastic+leukemia+(T-ALL):+New+insights+into+the+cellular+origins+and+infiltration+mechanisms+common+and+unique+among+hematologic+malignancies&amp;author=E.+Vadillo&amp;author=E.+Dorantes-Acosta&amp;author=R.+Pelayo&amp;author=M.+Schnoor&amp;volume=32&amp;publication_year=2018&amp;pages=36-51&amp;pmid=28830639&amp;doi=10.1016/j.blre.2017.08.006&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2-ijms-24-14646">2. <span class="element-citation">Jain N., Lamb A.V., O&#x02019;Brien S., Ravandi F., Konopleva M., Jabbour E., Zuo Z., Jorgensen J., Lin P., Pierce S., et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: A high-risk subtype. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:1863–1869. doi: 10.1182/blood-2015-08-661702.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4915808/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26747249" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood-2015-08-661702" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Early+T-cell+precursor+acute+lymphoblastic+leukemia/lymphoma+(ETP-ALL/LBL)+in+adolescents+and+adults:+A+high-risk+subtype&amp;author=N.+Jain&amp;author=A.V.+Lamb&amp;author=S.+O&#x02019;Brien&amp;author=F.+Ravandi&amp;author=M.+Konopleva&amp;volume=127&amp;publication_year=2016&amp;pages=1863-1869&amp;pmid=26747249&amp;doi=10.1182/blood-2015-08-661702&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3-ijms-24-14646">3. <span class="element-citation">Sin C.F., Man P.M. Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies. <span><span class="ref-journal">Front. Oncol. </span>2021;<span class="ref-vol">11</span>:750789. doi: 10.3389/fonc.2021.750789.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8666570/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34912707" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2021.750789" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=Early+T-Cell+Precursor+Acute+Lymphoblastic+Leukemia:+Diagnosis,+Updates+in+Molecular+Pathogenesis,+Management,+and+Novel+Therapies&amp;author=C.F.+Sin&amp;author=P.M.+Man&amp;volume=11&amp;publication_year=2021&amp;pages=750789&amp;pmid=34912707&amp;doi=10.3389/fonc.2021.750789&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4-ijms-24-14646">4. <span class="element-citation">Belver L., Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. <span><span class="ref-journal">Nat. Rev. Cancer. </span>2016;<span class="ref-vol">16</span>:494–507. doi: 10.1038/nrc.2016.63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27451956" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc.2016.63" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Cancer&amp;title=The+genetics+and+mechanisms+of+T+cell+acute+lymphoblastic+leukaemia&amp;author=L.+Belver&amp;author=A.+Ferrando&amp;volume=16&amp;publication_year=2016&amp;pages=494-507&amp;pmid=27451956&amp;doi=10.1038/nrc.2016.63&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5-ijms-24-14646">5. <span class="element-citation">Sawai C.M., Freund J., Oh P., Ndiaye-Lobry D., Bretz J.C., Strikoudis A., Genesca L., Trimarchi T., Kelliher M.A., Clark M., et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. <span><span class="ref-journal">Cancer Cell. </span>2012;<span class="ref-vol">22</span>:452–465. doi: 10.1016/j.ccr.2012.09.016.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3493168/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23079656" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ccr.2012.09.016" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Therapeutic+targeting+of+the+cyclin+D3:CDK4/6+complex+in+T+cell+leukemia&amp;author=C.M.+Sawai&amp;author=J.+Freund&amp;author=P.+Oh&amp;author=D.+Ndiaye-Lobry&amp;author=J.C.+Bretz&amp;volume=22&amp;publication_year=2012&amp;pages=452-465&amp;pmid=23079656&amp;doi=10.1016/j.ccr.2012.09.016&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6-ijms-24-14646">6. <span class="element-citation">Pikman Y., Alexe G., Roti G., Conway A.S., Furman A., Lee E.S., Place A.E., Kim S., Saran C., Modiste R., et al. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. <span><span class="ref-journal">Clin. Cancer Res. </span>2017;<span class="ref-vol">23</span>:1012–1024. doi: 10.1158/1078-0432.CCR-15-2869.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5432118/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28151717" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-15-2869" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Cancer+Res.&amp;title=Synergistic+Drug+Combinations+with+a+CDK4/6+Inhibitor+in+T-cell+Acute+Lymphoblastic+Leukemia&amp;author=Y.+Pikman&amp;author=G.+Alexe&amp;author=G.+Roti&amp;author=A.S.+Conway&amp;author=A.+Furman&amp;volume=23&amp;publication_year=2017&amp;pages=1012-1024&amp;pmid=28151717&amp;doi=10.1158/1078-0432.CCR-15-2869&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7-ijms-24-14646">7. <span class="element-citation">Jammal N., Rausch C.R., Kadia T.M., Pemmaraju N. Cell cycle inhibitors for the treatment of acute myeloid leukemia: A review of phase 2 &#x00026; 3 clinical trials. <span><span class="ref-journal">Expert. Opin. Emerg. Drugs. </span>2020;<span class="ref-vol">25</span>:491–499. doi: 10.1080/14728214.2020.1847272.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33161749" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F14728214.2020.1847272" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert.+Opin.+Emerg.+Drugs&amp;title=Cell+cycle+inhibitors+for+the+treatment+of+acute+myeloid+leukemia:+A+review+of+phase+2+&#x00026;+3+clinical+trials&amp;author=N.+Jammal&amp;author=C.R.+Rausch&amp;author=T.M.+Kadia&amp;author=N.+Pemmaraju&amp;volume=25&amp;publication_year=2020&amp;pages=491-499&amp;pmid=33161749&amp;doi=10.1080/14728214.2020.1847272&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8-ijms-24-14646">8. <span class="element-citation">Arkwright R., Pham T.M., Zonder J.A., Dou Q.P. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. <span><span class="ref-journal">Expert. Opin. Drug Discov. </span>2017;<span class="ref-vol">12</span>:225–235. doi: 10.1080/17460441.2017.1268596.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5520581/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27917682" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1080%2F17460441.2017.1268596" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert.+Opin.+Drug+Discov.&amp;title=The+preclinical+discovery+and+development+of+bortezomib+for+the+treatment+of+mantle+cell+lymphoma&amp;author=R.+Arkwright&amp;author=T.M.+Pham&amp;author=J.A.+Zonder&amp;author=Q.P.+Dou&amp;volume=12&amp;publication_year=2017&amp;pages=225-235&amp;pmid=27917682&amp;doi=10.1080/17460441.2017.1268596&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9-ijms-24-14646">9. <span class="element-citation">Hambley B., Caimi P.F., William B.M. Bortezomib for the treatment of mantle cell lymphoma: An update. <span><span class="ref-journal">Ther. Adv. Hematol. </span>2016;<span class="ref-vol">7</span>:196–208. doi: 10.1177/2040620716648566.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4959639/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27493710" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1177%2F2040620716648566" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ther.+Adv.+Hematol.&amp;title=Bortezomib+for+the+treatment+of+mantle+cell+lymphoma:+An+update&amp;author=B.+Hambley&amp;author=P.F.+Caimi&amp;author=B.M.+William&amp;volume=7&amp;publication_year=2016&amp;pages=196-208&amp;pmid=27493710&amp;doi=10.1177/2040620716648566&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10-ijms-24-14646">10. <span class="element-citation">Du X., Tong J., Lu H., He C., Du S., Jia P., Zhao W., Xu H., Li J., Shen Z., et al. Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. <span><span class="ref-journal">Mol. Med. Rep. </span>2017;<span class="ref-vol">16</span>:101–108. doi: 10.3892/mmr.2017.6554.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5482122/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28487980" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3892%2Fmmr.2017.6554" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol.+Med.+Rep.&amp;title=Combination+of+bortezomib+and+daunorubicin+in+the+induction+of+apoptosis+in+T-cell+acute+lymphoblastic+leukemia&amp;author=X.+Du&amp;author=J.+Tong&amp;author=H.+Lu&amp;author=C.+He&amp;author=S.+Du&amp;volume=16&amp;publication_year=2017&amp;pages=101-108&amp;pmid=28487980&amp;doi=10.3892/mmr.2017.6554&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11-ijms-24-14646">11. <span class="element-citation">Messinger Y.H., Gaynon P.S., Sposto R., van der Giessen J., Eckroth E., Malvar J., Bostrom B.C., Therapeutic Advances in Childhood Leukemia &#x00026; Lymphoma (TACL) Consortium  Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia &#x00026; Lymphoma (TACL) Study. <span><span class="ref-journal">Blood. </span>2012;<span class="ref-vol">120</span>:285–290. doi: 10.1182/blood-2012-04-418640.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22653976" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood-2012-04-418640" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Bortezomib+with+chemotherapy+is+highly+active+in+advanced+B-precursor+acute+lymphoblastic+leukemia:+Therapeutic+Advances+in+Childhood+Leukemia+&#x00026;+Lymphoma+(TACL)+Study&amp;author=Y.H.+Messinger&amp;author=P.S.+Gaynon&amp;author=R.+Sposto&amp;author=J.+van+der+Giessen&amp;author=E.+Eckroth&amp;volume=120&amp;publication_year=2012&amp;pages=285-290&amp;pmid=22653976&amp;doi=10.1182/blood-2012-04-418640&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12-ijms-24-14646">12. <span class="element-citation">Sin C.F., Man P.M. The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia. <span><span class="ref-journal">Front. Oncol. </span>2021;<span class="ref-vol">11</span>:802832. doi: 10.3389/fonc.2021.802832.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8733464/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35004327" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffonc.2021.802832" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Oncol.&amp;title=The+Role+of+Proteasome+Inhibitors+in+Treating+Acute+Lymphoblastic+Leukaemia&amp;author=C.F.+Sin&amp;author=P.M.+Man&amp;volume=11&amp;publication_year=2021&amp;pages=802832&amp;pmid=35004327&amp;doi=10.3389/fonc.2021.802832&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13-ijms-24-14646">13. <span class="element-citation">Dewar R., Chen S.T., Yeckes-Rodin H., Miller K., Khosravi-Far R. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker. <span><span class="ref-journal">Cancer Biol. Ther. </span>2011;<span class="ref-vol">11</span>:552–558. doi: 10.4161/cbt.11.6.14675.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3087959/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21282974" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fcbt.11.6.14675" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Biol.+Ther.&amp;title=Bortezomib+treatment+causes+remission+in+a+Ph+ALL+patient+and+reveals+FoxO+as+a+theranostic+marker&amp;author=R.+Dewar&amp;author=S.T.+Chen&amp;author=H.+Yeckes-Rodin&amp;author=K.+Miller&amp;author=R.+Khosravi-Far&amp;volume=11&amp;publication_year=2011&amp;pages=552-558&amp;pmid=21282974&amp;doi=10.4161/cbt.11.6.14675&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14-ijms-24-14646">14. <span class="element-citation">Koyama D., Kikuchi J., Hiraoka N., Wada T., Kurosawa H., Chiba S., Furukawa Y. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. <span><span class="ref-journal">Leukemia. </span>2014;<span class="ref-vol">28</span>:1216–1226. doi: 10.1038/leu.2013.366.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4051216/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24301524" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fleu.2013.366" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Proteasome+inhibitors+exert+cytotoxicity+and+increase+chemosensitivity+via+transcriptional+repression+of+Notch1+in+T-cell+acute+lymphoblastic+leukemia&amp;author=D.+Koyama&amp;author=J.+Kikuchi&amp;author=N.+Hiraoka&amp;author=T.+Wada&amp;author=H.+Kurosawa&amp;volume=28&amp;publication_year=2014&amp;pages=1216-1226&amp;pmid=24301524&amp;doi=10.1038/leu.2013.366&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15-ijms-24-14646">15. <span class="element-citation">Albero M.P., Vaquer J.M., Andreu E.J., Villanueva J.J., Franch L., Ivorra C., Poch E., Agirre X., Prosper F. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. <span><span class="ref-journal">Oncogene. </span>2010;<span class="ref-vol">29</span>:3276–3286. doi: 10.1038/onc.2010.81.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20305692" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fonc.2010.81" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Bortezomib+decreases+Rb+phosphorylation+and+induces+caspase-dependent+apoptosis+in+Imatinib-sensitive+and+-resistant+Bcr-Abl1-expressing+cells&amp;author=M.P.+Albero&amp;author=J.M.+Vaquer&amp;author=E.J.+Andreu&amp;author=J.J.+Villanueva&amp;author=L.+Franch&amp;volume=29&amp;publication_year=2010&amp;pages=3276-3286&amp;pmid=20305692&amp;doi=10.1038/onc.2010.81&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16-ijms-24-14646">16. <span class="element-citation">Hutter G., Rieken M., Pastore A., Weigert O., Zimmermann Y., Weinkauf M., Hiddemann W., Dreyling M. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma. <span><span class="ref-journal">Ann. Hematol. </span>2012;<span class="ref-vol">91</span>:847–856. doi: 10.1007/s00277-011-1377-y.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22231280" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00277-011-1377-y" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann.+Hematol.&amp;title=The+proteasome+inhibitor+bortezomib+targets+cell+cycle+and+apoptosis+and+acts+synergistically+in+a+sequence-dependent+way+with+chemotherapeutic+agents+in+mantle+cell+lymphoma&amp;author=G.+Hutter&amp;author=M.+Rieken&amp;author=A.+Pastore&amp;author=O.+Weigert&amp;author=Y.+Zimmermann&amp;volume=91&amp;publication_year=2012&amp;pages=847-856&amp;pmid=22231280&amp;doi=10.1007/s00277-011-1377-y&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17-ijms-24-14646">17. <span class="element-citation">Yin D., Zhou H., Kumagai T., Liu G., Ong J.M., Black K.L., Koeffler H.P. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) <span><span class="ref-journal">Oncogene. </span>2005;<span class="ref-vol">24</span>:344–354. doi: 10.1038/sj.onc.1208225.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15531918" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1208225" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Proteasome+inhibitor+PS-341+causes+cell+growth+arrest+and+apoptosis+in+human+glioblastoma+multiforme+(GBM)&amp;author=D.+Yin&amp;author=H.+Zhou&amp;author=T.+Kumagai&amp;author=G.+Liu&amp;author=J.M.+Ong&amp;volume=24&amp;publication_year=2005&amp;pages=344-354&amp;pmid=15531918&amp;doi=10.1038/sj.onc.1208225&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18-ijms-24-14646">18. <span class="element-citation">Ling Y.H., Liebes L., Jiang J.D., Holland J.F., Elliott P.J., Adams J., Muggia F.M., Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. <span><span class="ref-journal">Clin. Cancer Res. </span>2003;<span class="ref-vol">9</span>:1145–1154.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12631620" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Cancer+Res.&amp;title=Mechanisms+of+proteasome+inhibitor+PS-341-induced+G(2)-M-phase+arrest+and+apoptosis+in+human+non-small+cell+lung+cancer+cell+lines&amp;author=Y.H.+Ling&amp;author=L.+Liebes&amp;author=J.D.+Jiang&amp;author=J.F.+Holland&amp;author=P.J.+Elliott&amp;volume=9&amp;publication_year=2003&amp;pages=1145-1154&amp;pmid=12631620&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19-ijms-24-14646">19. <span class="element-citation">Do K., Doroshow J.H., Kummar S. Wee1 kinase as a target for cancer therapy. <span><span class="ref-journal">Cell Cycle. </span>2013;<span class="ref-vol">12</span>:3159–3164. doi: 10.4161/cc.26062.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3865011/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24013427" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.4161%2Fcc.26062" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Cycle&amp;title=Wee1+kinase+as+a+target+for+cancer+therapy&amp;author=K.+Do&amp;author=J.H.+Doroshow&amp;author=S.+Kummar&amp;volume=12&amp;publication_year=2013&amp;pages=3159-3164&amp;pmid=24013427&amp;doi=10.4161/cc.26062&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20-ijms-24-14646">20. <span class="element-citation">Ghelli Luserna Di Rora A., Beeharry N., Imbrogno E., Ferrari A., Robustelli V., Righi S., Sabattini E., Verga Falzacappa M.V., Ronchini C., Testoni N., et al. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <span><span class="ref-journal">J. Hematol. Oncol. </span>2018;<span class="ref-vol">11</span>:99. doi: 10.1186/s13045-018-0641-1.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6090987/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30068368" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs13045-018-0641-1" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Hematol.+Oncol.&amp;title=Targeting+WEE1+to+enhance+conventional+therapies+for+acute+lymphoblastic+leukemia&amp;author=A.+Ghelli+Luserna+Di+Rora&amp;author=N.+Beeharry&amp;author=E.+Imbrogno&amp;author=A.+Ferrari&amp;author=V.+Robustelli&amp;volume=11&amp;publication_year=2018&amp;pages=99&amp;pmid=30068368&amp;doi=10.1186/s13045-018-0641-1&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21-ijms-24-14646">21. <span class="element-citation">Slipicevic A., Holth A., Hellesylt E., Trope C.G., Davidson B., Florenes V.A. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. <span><span class="ref-journal">Gynecol. Oncol. </span>2014;<span class="ref-vol">135</span>:118–124. doi: 10.1016/j.ygyno.2014.07.102.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25093290" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ygyno.2014.07.102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.+Oncol.&amp;title=Wee1+is+a+novel+independent+prognostic+marker+of+poor+survival+in+post-chemotherapy+ovarian+carcinoma+effusions&amp;author=A.+Slipicevic&amp;author=A.+Holth&amp;author=E.+Hellesylt&amp;author=C.G.+Trope&amp;author=B.+Davidson&amp;volume=135&amp;publication_year=2014&amp;pages=118-124&amp;pmid=25093290&amp;doi=10.1016/j.ygyno.2014.07.102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22-ijms-24-14646">22. <span class="element-citation">Magnussen G.I., Holm R., Emilsen E., Rosnes A.K., Slipicevic A., Florenes V.A. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. <span><span class="ref-journal">PLoS ONE. </span>2012;<span class="ref-vol">7</span>:e38254.  doi: 10.1371/journal.pone.0038254.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3373567/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22719872" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pone.0038254" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=High+expression+of+Wee1+is+associated+with+poor+disease-free+survival+in+malignant+melanoma:+Potential+for+targeted+therapy&amp;author=G.I.+Magnussen&amp;author=R.+Holm&amp;author=E.+Emilsen&amp;author=A.K.+Rosnes&amp;author=A.+Slipicevic&amp;volume=7&amp;publication_year=2012&amp;pages=e38254&amp;pmid=22719872&amp;doi=10.1371/journal.pone.0038254&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23-ijms-24-14646">23. <span class="element-citation">Ge X.C., Wu F., Li W.T., Zhu X.J., Liu J.W., Wang B.L. Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. <span><span class="ref-journal">Oncol. Lett. </span>2017;<span class="ref-vol">13</span>:4341–4348. doi: 10.3892/ol.2017.5984.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5453116/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28599436" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3892%2Fol.2017.5984" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncol.+Lett.&amp;title=Upregulation+of+WEE1+is+a+potential+prognostic+biomarker+for+patients+with+colorectal+cancer&amp;author=X.C.+Ge&amp;author=F.+Wu&amp;author=W.T.+Li&amp;author=X.J.+Zhu&amp;author=J.W.+Liu&amp;volume=13&amp;publication_year=2017&amp;pages=4341-4348&amp;pmid=28599436&amp;doi=10.3892/ol.2017.5984&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24-ijms-24-14646">24. <span class="element-citation">Chun-fung S.I.N., Wan T.M.-h., Mohan A.A.M., Qiu Y., Jiao A. Bortezomib Is Effective in Treating T-ALL, Inducting G2/M Cell Cycle Arrest and WEE1 Downregulation. <span><span class="ref-journal">Blood. </span>2021;<span class="ref-vol">138</span>:4360. doi: 10.1182/blood-2021-149455.</span> [<a href="//doi.org/10.1182%2Fblood-2021-149455" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Bortezomib+Is+Effective+in+Treating+T-ALL,+Inducting+G2/M+Cell+Cycle+Arrest+and+WEE1+Downregulation&amp;author=S.I.N.+Chun-fung&amp;author=T.M.-h.+Wan&amp;author=A.A.M.+Mohan&amp;author=Y.+Qiu&amp;author=A.+Jiao&amp;volume=138&amp;publication_year=2021&amp;pages=4360&amp;doi=10.1182/blood-2021-149455&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25-ijms-24-14646">25. <span class="element-citation">Cron K.R., Zhu K., Kushwaha D.S., Hsieh G., Merzon D., Rameseder J., Chen C.C., D&#x02019;Andrea A.D., Kozono D. Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. <span><span class="ref-journal">PLoS ONE. </span>2013;<span class="ref-vol">8</span>:e73710.  doi: 10.1371/journal.pone.0073710.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3764058/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24040035" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pone.0073710" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Proteasome+inhibitors+block+DNA+repair+and+radiosensitize+non-small+cell+lung+cancer&amp;author=K.R.+Cron&amp;author=K.+Zhu&amp;author=D.S.+Kushwaha&amp;author=G.+Hsieh&amp;author=D.+Merzon&amp;volume=8&amp;publication_year=2013&amp;pages=e73710&amp;pmid=24040035&amp;doi=10.1371/journal.pone.0073710&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26-ijms-24-14646">26. <span class="element-citation">De Witt Hamer P.C., Mir S.E., Noske D., Van Noorden C.J., Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. <span><span class="ref-journal">Clin. Cancer Res. </span>2011;<span class="ref-vol">17</span>:4200–4207. doi: 10.1158/1078-0432.CCR-10-2537.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21562035" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1078-0432.CCR-10-2537" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin.+Cancer+Res.&amp;title=WEE1+kinase+targeting+combined+with+DNA-damaging+cancer+therapy+catalyzes+mitotic+catastrophe&amp;author=P.C.+De+Witt+Hamer&amp;author=S.E.+Mir&amp;author=D.+Noske&amp;author=C.J.+Van+Noorden&amp;author=T.+Wurdinger&amp;volume=17&amp;publication_year=2011&amp;pages=4200-4207&amp;pmid=21562035&amp;doi=10.1158/1078-0432.CCR-10-2537&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27-ijms-24-14646">27. <span class="element-citation">El Ghamrasni S., Pamidi A., Halaby M.J., Bohgaki M., Cardoso R., Li L., Venkatesan S., Sethu S., Hirao A., Mak T.W., et al. Inactivation of chk2 and mus81 leads to impaired lymphocytes development, reduced genomic instability, and suppression of cancer. <span><span class="ref-journal">PLoS Genet. </span>2011;<span class="ref-vol">7</span>:e1001385.  doi: 10.1371/journal.pgen.1001385.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3098187/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21625617" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1371%2Fjournal.pgen.1001385" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+Genet.&amp;title=Inactivation+of+chk2+and+mus81+leads+to+impaired+lymphocytes+development,+reduced+genomic+instability,+and+suppression+of+cancer&amp;author=S.+El+Ghamrasni&amp;author=A.+Pamidi&amp;author=M.J.+Halaby&amp;author=M.+Bohgaki&amp;author=R.+Cardoso&amp;volume=7&amp;publication_year=2011&amp;pages=e1001385&amp;pmid=21625617&amp;doi=10.1371/journal.pgen.1001385&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28-ijms-24-14646">28. <span class="element-citation">Skwarska A., Ramachandran S., Dobrynin G., Leszczynska K.B., Hammond E.M. The imidazoacridinone C-1311 induces p53-dependent senescence or p53-independent apoptosis and sensitizes cancer cells to radiation. <span><span class="ref-journal">Oncotarget. </span>2017;<span class="ref-vol">8</span>:31187–31198. doi: 10.18632/oncotarget.16102.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5458200/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28415717" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.16102" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The+imidazoacridinone+C-1311+induces+p53-dependent+senescence+or+p53-independent+apoptosis+and+sensitizes+cancer+cells+to+radiation&amp;author=A.+Skwarska&amp;author=S.+Ramachandran&amp;author=G.+Dobrynin&amp;author=K.B.+Leszczynska&amp;author=E.M.+Hammond&amp;volume=8&amp;publication_year=2017&amp;pages=31187-31198&amp;pmid=28415717&amp;doi=10.18632/oncotarget.16102&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29-ijms-24-14646">29. <span class="element-citation">Maskey D., Yousefi S., Schmid I., Zlobec I., Perren A., Friis R., Simon H.U. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. <span><span class="ref-journal">Nat. Commun. </span>2013;<span class="ref-vol">4</span>:2130. doi: 10.1038/ncomms3130.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3753548/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23945651" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fncomms3130" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Commun.&amp;title=ATG5+is+induced+by+DNA-damaging+agents+and+promotes+mitotic+catastrophe+independent+of+autophagy&amp;author=D.+Maskey&amp;author=S.+Yousefi&amp;author=I.+Schmid&amp;author=I.+Zlobec&amp;author=A.+Perren&amp;volume=4&amp;publication_year=2013&amp;pages=2130&amp;pmid=23945651&amp;doi=10.1038/ncomms3130&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30-ijms-24-14646">30. <span class="element-citation">Koryllou A., Patrinou-Georgoula M., Troungos C., Pletsa V. Cell death induced by N-methyl-N-nitrosourea, a model S(N)1 methylating agent, in two lung cancer cell lines of human origin. <span><span class="ref-journal">Apoptosis. </span>2009;<span class="ref-vol">14</span>:1121–1133. doi: 10.1007/s10495-009-0379-x.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19634013" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs10495-009-0379-x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Apoptosis&amp;title=Cell+death+induced+by+N-methyl-N-nitrosourea,+a+model+S(N)1+methylating+agent,+in+two+lung+cancer+cell+lines+of+human+origin&amp;author=A.+Koryllou&amp;author=M.+Patrinou-Georgoula&amp;author=C.+Troungos&amp;author=V.+Pletsa&amp;volume=14&amp;publication_year=2009&amp;pages=1121-1133&amp;pmid=19634013&amp;doi=10.1007/s10495-009-0379-x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31-ijms-24-14646">31. <span class="element-citation">Miyake K., Takano N., Kazama H., Kikuchi H., Hiramoto M., Tsukahara K., Miyazawa K. Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells. <span><span class="ref-journal">Int. J. Oncol. </span>2022;<span class="ref-vol">60</span>:54. doi: 10.3892/ijo.2022.5344.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC8997343/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35348191" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3892%2Fijo.2022.5344" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int.+J.+Oncol.&amp;title=Ricolinostat+enhances+adavosertib-induced+mitotic+catastrophe+in+TP53-mutated+head+and+neck+squamous+cell+carcinoma+cells&amp;author=K.+Miyake&amp;author=N.+Takano&amp;author=H.+Kazama&amp;author=H.+Kikuchi&amp;author=M.+Hiramoto&amp;volume=60&amp;publication_year=2022&amp;pages=54&amp;pmid=35348191&amp;doi=10.3892/ijo.2022.5344&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32-ijms-24-14646">32. <span class="element-citation">Marks D.I., Rowntree C. Management of adults with T-cell lymphoblastic leukemia. <span><span class="ref-journal">Blood. </span>2017;<span class="ref-vol">129</span>:1134–1142. doi: 10.1182/blood-2016-07-692608.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28115371" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood-2016-07-692608" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Management+of+adults+with+T-cell+lymphoblastic+leukemia&amp;author=D.I.+Marks&amp;author=C.+Rowntree&amp;volume=129&amp;publication_year=2017&amp;pages=1134-1142&amp;pmid=28115371&amp;doi=10.1182/blood-2016-07-692608&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33-ijms-24-14646">33. <span class="element-citation">Wu W., Nie L., Zhang L., Li Y. The notch pathway promotes NF-kappaB activation through Asb2 in T cell acute lymphoblastic leukemia cells. <span><span class="ref-journal">Cell Mol. Biol. Lett. </span>2018;<span class="ref-vol">23</span>:37.  doi: 10.1186/s11658-018-0102-4.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6085606/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30116272" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1186%2Fs11658-018-0102-4" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Mol.+Biol.+Lett.&amp;title=The+notch+pathway+promotes+NF-kappaB+activation+through+Asb2+in+T+cell+acute+lymphoblastic+leukemia+cells&amp;author=W.+Wu&amp;author=L.+Nie&amp;author=L.+Zhang&amp;author=Y.+Li&amp;volume=23&amp;publication_year=2018&amp;pages=37&amp;pmid=30116272&amp;doi=10.1186/s11658-018-0102-4&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34-ijms-24-14646">34. <span class="element-citation">Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., Thompson B., Spaulding C., Macaroun S., Alegre M.L., et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. <span><span class="ref-journal">Nat. Med. </span>2007;<span class="ref-vol">13</span>:70–77. doi: 10.1038/nm1524.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17173050" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnm1524" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Med.&amp;title=Targeting+the+NF-kappaB+signaling+pathway+in+Notch1-induced+T-cell+leukemia&amp;author=T.+Vilimas&amp;author=J.+Mascarenhas&amp;author=T.+Palomero&amp;author=M.+Mandal&amp;author=S.+Buonamici&amp;volume=13&amp;publication_year=2007&amp;pages=70-77&amp;pmid=17173050&amp;doi=10.1038/nm1524&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35-ijms-24-14646">35. <span class="element-citation">Buontempo F., Orsini E., Lonetti A., Cappellini A., Chiarini F., Evangelisti C., Evangelisti C., Melchionda F., Pession A., Bertaina A., et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. <span><span class="ref-journal">Oncotarget. </span>2016;<span class="ref-vol">7</span>:1323–1340. doi: 10.18632/oncotarget.6361.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4811463/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26593250" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.18632%2Foncotarget.6361" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Synergistic+cytotoxic+effects+of+bortezomib+and+CK2+inhibitor+CX-4945+in+acute+lymphoblastic+leukemia:+Turning+off+the+prosurvival+ER+chaperone+BIP/Grp78+and+turning+on+the+pro-apoptotic+NF-kappaB&amp;author=F.+Buontempo&amp;author=E.+Orsini&amp;author=A.+Lonetti&amp;author=A.+Cappellini&amp;author=F.+Chiarini&amp;volume=7&amp;publication_year=2016&amp;pages=1323-1340&amp;pmid=26593250&amp;doi=10.18632/oncotarget.6361&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36-ijms-24-14646">36. <span class="element-citation">Dai Y., Chen S., Wang L., Pei X.Y., Kramer L.B., Dent P., Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-kappaB and Bim. <span><span class="ref-journal">Br. J. Haematol. </span>2011;<span class="ref-vol">153</span>:222–235. doi: 10.1111/j.1365-2141.2011.08591.x.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3358826/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21375523" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1365-2141.2011.08591.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br.+J.+Haematol.&amp;title=Bortezomib+interacts+synergistically+with+belinostat+in+human+acute+myeloid+leukaemia+and+acute+lymphoblastic+leukaemia+cells+in+association+with+perturbations+in+NF-kappaB+and+Bim&amp;author=Y.+Dai&amp;author=S.+Chen&amp;author=L.+Wang&amp;author=X.Y.+Pei&amp;author=L.B.+Kramer&amp;volume=153&amp;publication_year=2011&amp;pages=222-235&amp;pmid=21375523&amp;doi=10.1111/j.1365-2141.2011.08591.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37-ijms-24-14646">37. <span class="element-citation">Roti G., Qi J., Kitara S., Sanchez-Martin M., Saur Conway A., Varca A.C., Su A., Wu L., Kung A.L., Ferrando A.A., et al. Leukemia-specific delivery of mutant NOTCH1 targeted therapy. <span><span class="ref-journal">J. Exp. Med. </span>2018;<span class="ref-vol">215</span>:197–216. doi: 10.1084/jem.20151778.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5748843/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29158376" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1084%2Fjem.20151778" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Exp.+Med.&amp;title=Leukemia-specific+delivery+of+mutant+NOTCH1+targeted+therapy&amp;author=G.+Roti&amp;author=J.+Qi&amp;author=S.+Kitara&amp;author=M.+Sanchez-Martin&amp;author=A.+Saur+Conway&amp;volume=215&amp;publication_year=2018&amp;pages=197-216&amp;pmid=29158376&amp;doi=10.1084/jem.20151778&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38-ijms-24-14646">38. <span class="element-citation">Anderson K.C., Palladino M., Munshi N., Richardson P., Schlossman R., Hideshima T., Podar K., Brahmandam M., Singh A., Chauhan D. Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:2524. doi: 10.1182/blood.V110.11.2524.2524.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2214767/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18006697" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1182%2Fblood.V110.11.2524.2524" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Combination+of+Proteasome+Inhibitors+Bortezomib+and+NPI-0052+Trigger+In+Vivo+Synergistic+Cytotoxicity+in+Multiple+Myeloma&amp;author=K.C.+Anderson&amp;author=M.+Palladino&amp;author=N.+Munshi&amp;author=P.+Richardson&amp;author=R.+Schlossman&amp;volume=110&amp;publication_year=2007&amp;pages=2524&amp;doi=10.1182/blood.V110.11.2524.2524&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39-ijms-24-14646">39. <span class="element-citation">Jung H.J., Chen Z., Fayad L., Wang M., Romaguera J., Kwak L.W., McCarty N. Bortezomib-resistant nuclear factor kappaB expression in stem-like cells in mantle cell lymphoma. <span><span class="ref-journal">Exp. Hematol. </span>2012;<span class="ref-vol">40</span>:107–118. doi: 10.1016/j.exphem.2011.10.004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3398482/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22024108" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.exphem.2011.10.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Exp.+Hematol.&amp;title=Bortezomib-resistant+nuclear+factor+kappaB+expression+in+stem-like+cells+in+mantle+cell+lymphoma&amp;author=H.J.+Jung&amp;author=Z.+Chen&amp;author=L.+Fayad&amp;author=M.+Wang&amp;author=J.+Romaguera&amp;volume=40&amp;publication_year=2012&amp;pages=107-118&amp;pmid=22024108&amp;doi=10.1016/j.exphem.2011.10.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40-ijms-24-14646">40. <span class="element-citation">Cipolla L., Maffia A., Bertoletti F., Sabbioneda S. The Regulation of DNA Damage Tolerance by Ubiquitin and Ubiquitin-Like Modifiers. <span><span class="ref-journal">Front. Genet. </span>2016;<span class="ref-vol">7</span>:105. doi: 10.3389/fgene.2016.00105.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4904029/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27379156" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3389%2Ffgene.2016.00105" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Front.+Genet.&amp;title=The+Regulation+of+DNA+Damage+Tolerance+by+Ubiquitin+and+Ubiquitin-Like+Modifiers&amp;author=L.+Cipolla&amp;author=A.+Maffia&amp;author=F.+Bertoletti&amp;author=S.+Sabbioneda&amp;volume=7&amp;publication_year=2016&amp;pages=105&amp;pmid=27379156&amp;doi=10.3389/fgene.2016.00105&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41-ijms-24-14646">41. <span class="element-citation">Briest F., Koziolek E.J., Albrecht J., Schmidt F., Bernsen M.R., Haeck J., Kuhl A.A., Sedding D., Hartung T., Exner S., et al. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms?&#x02014;A preclinical assessment in vitro and in vivo. <span><span class="ref-journal">Neoplasia. </span>2021;<span class="ref-vol">23</span>:80–98. doi: 10.1016/j.neo.2020.11.004.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7701025/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33246310" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.neo.2020.11.004" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;title=Does+the+proteasome+inhibitor+bortezomib+sensitize+to+DNA-damaging+therapy+in+gastroenteropancreatic+neuroendocrine+neoplasms?&#x02014;A+preclinical+assessment+in+vitro+and+in+vivo&amp;author=F.+Briest&amp;author=E.J.+Koziolek&amp;author=J.+Albrecht&amp;author=F.+Schmidt&amp;author=M.R.+Bernsen&amp;volume=23&amp;publication_year=2021&amp;pages=80-98&amp;pmid=33246310&amp;doi=10.1016/j.neo.2020.11.004&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42-ijms-24-14646">42. <span class="element-citation">Takeshita T., Wu W., Koike A., Fukuda M., Ohta T. Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. <span><span class="ref-journal">Cancer Chemother. Pharmacol. </span>2009;<span class="ref-vol">64</span>:1039–1046. doi: 10.1007/s00280-009-0961-5.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2728221/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19274461" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs00280-009-0961-5" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Chemother.+Pharmacol.&amp;title=Perturbation+of+DNA+repair+pathways+by+proteasome+inhibitors+corresponds+to+enhanced+chemosensitivity+of+cells+to+DNA+damage-inducing+agents&amp;author=T.+Takeshita&amp;author=W.+Wu&amp;author=A.+Koike&amp;author=M.+Fukuda&amp;author=T.+Ohta&amp;volume=64&amp;publication_year=2009&amp;pages=1039-1046&amp;pmid=19274461&amp;doi=10.1007/s00280-009-0961-5&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43-ijms-24-14646">43. <span class="element-citation">Chene P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. <span><span class="ref-journal">Nat. Rev. Cancer. </span>2003;<span class="ref-vol">3</span>:102–109. doi: 10.1038/nrc991.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12563309" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fnrc991" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Rev.+Cancer&amp;title=Inhibiting+the+p53-MDM2+interaction:+An+important+target+for+cancer+therapy&amp;author=P.+Chene&amp;volume=3&amp;publication_year=2003&amp;pages=102-109&amp;pmid=12563309&amp;doi=10.1038/nrc991&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44-ijms-24-14646">44. <span class="element-citation">Lakin N.D., Jackson S.P. Regulation of p53 in response to DNA damage. <span><span class="ref-journal">Oncogene. </span>1999;<span class="ref-vol">18</span>:7644–7655. doi: 10.1038/sj.onc.1203015.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10618704" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.onc.1203015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Regulation+of+p53+in+response+to+DNA+damage&amp;author=N.D.+Lakin&amp;author=S.P.+Jackson&amp;volume=18&amp;publication_year=1999&amp;pages=7644-7655&amp;pmid=10618704&amp;doi=10.1038/sj.onc.1203015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45-ijms-24-14646">45. <span class="element-citation">Yerlikaya A., Okur E., Ulukaya E. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. <span><span class="ref-journal">Tumour Biol. </span>2012;<span class="ref-vol">33</span>:1385–1392. doi: 10.1007/s13277-012-0386-3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22477712" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1007%2Fs13277-012-0386-3" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Tumour+Biol.&amp;title=The+p53-independent+induction+of+apoptosis+in+breast+cancer+cells+in+response+to+proteasome+inhibitor+bortezomib&amp;author=A.+Yerlikaya&amp;author=E.+Okur&amp;author=E.+Ulukaya&amp;volume=33&amp;publication_year=2012&amp;pages=1385-1392&amp;pmid=22477712&amp;doi=10.1007/s13277-012-0386-3&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46-ijms-24-14646">46. <span class="element-citation">Jin L., Tabe Y., Kojima K., Zhou Y., Pittaluga S., Konopleva M., Miida T., Raffeld M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. <span><span class="ref-journal">Cancer Lett. </span>2010;<span class="ref-vol">299</span>:161–170. doi: 10.1016/j.canlet.2010.08.015.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20850924" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.canlet.2010.08.015" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Lett.&amp;title=MDM2+antagonist+Nutlin-3+enhances+bortezomib-mediated+mitochondrial+apoptosis+in+TP53-mutated+mantle+cell+lymphoma&amp;author=L.+Jin&amp;author=Y.+Tabe&amp;author=K.+Kojima&amp;author=Y.+Zhou&amp;author=S.+Pittaluga&amp;volume=299&amp;publication_year=2010&amp;pages=161-170&amp;pmid=20850924&amp;doi=10.1016/j.canlet.2010.08.015&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47-ijms-24-14646">47. <span class="element-citation">Yu C.H., Chang W.T., Jou S.T., Lin T.K., Chang Y.H., Lin C.Y., Lin K.H., Lu M.Y., Chen S.H., Wu K.H., et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. <span><span class="ref-journal">Cancer Sci. </span>2020;<span class="ref-vol">111</span>:229–238. doi: 10.1111/cas.14238.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6942420/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31729120" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fcas.14238" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Sci.&amp;title=TP53+alterations+in+relapsed+childhood+acute+lymphoblastic+leukemia&amp;author=C.H.+Yu&amp;author=W.T.+Chang&amp;author=S.T.+Jou&amp;author=T.K.+Lin&amp;author=Y.H.+Chang&amp;volume=111&amp;publication_year=2020&amp;pages=229-238&amp;pmid=31729120&amp;doi=10.1111/cas.14238&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48-ijms-24-14646">48. <span class="element-citation">Rapino F., Naumann I., Fulda S. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. <span><span class="ref-journal">Cell Death Dis. </span>2013;<span class="ref-vol">4</span>:e925. doi: 10.1038/cddis.2013.440.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3847318/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24263099" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fcddis.2013.440" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Dis.&amp;title=Bortezomib+antagonizes+microtubule-interfering+drug-induced+apoptosis+by+inhibiting+G2/M+transition+and+MCL-1+degradation&amp;author=F.+Rapino&amp;author=I.+Naumann&amp;author=S.+Fulda&amp;volume=4&amp;publication_year=2013&amp;pages=e925&amp;pmid=24263099&amp;doi=10.1038/cddis.2013.440&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49-ijms-24-14646">49. <span class="element-citation">Bonvini P., Zorzi E., Basso G., Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. <span><span class="ref-journal">Leukemia. </span>2007;<span class="ref-vol">21</span>:838–842. doi: 10.1038/sj.leu.2404528.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17268529" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fsj.leu.2404528" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Leukemia&amp;title=Bortezomib-mediated+26S+proteasome+inhibition+causes+cell-cycle+arrest+and+induces+apoptosis+in+CD-30++anaplastic+large+cell+lymphoma&amp;author=P.+Bonvini&amp;author=E.+Zorzi&amp;author=G.+Basso&amp;author=A.+Rosolen&amp;volume=21&amp;publication_year=2007&amp;pages=838-842&amp;pmid=17268529&amp;doi=10.1038/sj.leu.2404528&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50-ijms-24-14646">50. <span class="element-citation">Strauss S.J., Higginbottom K., Juliger S., Maharaj L., Allen P., Schenkein D., Lister T.A., Joel S.P. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. <span><span class="ref-journal">Cancer Res. </span>2007;<span class="ref-vol">67</span>:2783–2790. doi: 10.1158/0008-5472.CAN-06-3254.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17363600" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F0008-5472.CAN-06-3254" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res.&amp;title=The+proteasome+inhibitor+bortezomib+acts+independently+of+p53+and+induces+cell+death+via+apoptosis+and+mitotic+catastrophe+in+B-cell+lymphoma+cell+lines&amp;author=S.J.+Strauss&amp;author=K.+Higginbottom&amp;author=S.+Juliger&amp;author=L.+Maharaj&amp;author=P.+Allen&amp;volume=67&amp;publication_year=2007&amp;pages=2783-2790&amp;pmid=17363600&amp;doi=10.1158/0008-5472.CAN-06-3254&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51-ijms-24-14646">51. <span class="element-citation">Liu H., Westergard T.D., Cashen A., Piwnica-Worms D.R., Kunkle L., Vij R., Pham C.G., DiPersio J., Cheng E.H., Hsieh J.J. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. <span><span class="ref-journal">Cancer Cell. </span>2014;<span class="ref-vol">25</span>:530–542. doi: 10.1016/j.ccr.2014.03.008.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4097146/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24735925" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.ccr.2014.03.008" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Proteasome+inhibitors+evoke+latent+tumor+suppression+programs+in+pro-B+MLL+leukemias+through+MLL-AF4&amp;author=H.+Liu&amp;author=T.D.+Westergard&amp;author=A.+Cashen&amp;author=D.R.+Piwnica-Worms&amp;author=L.+Kunkle&amp;volume=25&amp;publication_year=2014&amp;pages=530-542&amp;pmid=24735925&amp;doi=10.1016/j.ccr.2014.03.008&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52-ijms-24-14646">52. <span class="element-citation">Liang L., He Y., Wang H., Zhou H., Xiao L., Ye M., Kuang Y., Luo S., Zuo Y., Feng P., et al. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma. <span><span class="ref-journal">Br. J. Haematol. </span>2020;<span class="ref-vol">191</span>:62–76. doi: 10.1111/bjh.16614.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32314355" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fbjh.16614" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Br.+J.+Haematol.&amp;title=The+Wee1+kinase+inhibitor+MK1775+suppresses+cell+growth,+attenuates+stemness+and+synergises+with+bortezomib+in+multiple+myeloma&amp;author=L.+Liang&amp;author=Y.+He&amp;author=H.+Wang&amp;author=H.+Zhou&amp;author=L.+Xiao&amp;volume=191&amp;publication_year=2020&amp;pages=62-76&amp;pmid=32314355&amp;doi=10.1111/bjh.16614&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53-ijms-24-14646">53. <span class="element-citation">Van Linden A.A., Baturin D., Ford J.B., Fosmire S.P., Gardner L., Korch C., Reigan P., Porter C.C. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. <span><span class="ref-journal">Mol. Cancer Ther. </span>2013;<span class="ref-vol">12</span>:2675–2684. doi: 10.1158/1535-7163.MCT-13-0424.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3897395/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24121103" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-13-0424" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol.+Cancer+Ther.&amp;title=Inhibition+of+Wee1+sensitizes+cancer+cells+to+antimetabolite+chemotherapeutics+in+vitro+and+in+vivo,+independent+of+p53+functionality&amp;author=A.A.+Van+Linden&amp;author=D.+Baturin&amp;author=J.B.+Ford&amp;author=S.P.+Fosmire&amp;author=L.+Gardner&amp;volume=12&amp;publication_year=2013&amp;pages=2675-2684&amp;pmid=24121103&amp;doi=10.1158/1535-7163.MCT-13-0424&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54-ijms-24-14646">54. <span class="element-citation">Shen L., Au W.Y., Wong K.Y., Shimizu N., Tsuchiyama J., Kwong Y.L., Liang R.H., Srivastava G. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells. <span><span class="ref-journal">Mol. Cancer Ther. </span>2008;<span class="ref-vol">7</span>:3807–3815. doi: 10.1158/1535-7163.MCT-08-0641.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19074855" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1158%2F1535-7163.MCT-08-0641" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol.+Cancer+Ther.&amp;title=Cell+death+by+bortezomib-induced+mitotic+catastrophe+in+natural+killer+lymphoma+cells&amp;author=L.+Shen&amp;author=W.Y.+Au&amp;author=K.Y.+Wong&amp;author=N.+Shimizu&amp;author=J.+Tsuchiyama&amp;volume=7&amp;publication_year=2008&amp;pages=3807-3815&amp;pmid=19074855&amp;doi=10.1158/1535-7163.MCT-08-0641&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55-ijms-24-14646">55. <span class="element-citation">Tamura D., Arao T., Tanaka K., Kaneda H., Matsumoto K., Kudo K., Aomatsu K., Fujita Y., Watanabe T., Saijo N., et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. <span><span class="ref-journal">Cancer Sci. </span>2010;<span class="ref-vol">101</span>:1403–1408. doi: 10.1111/j.1349-7006.2010.01544.x.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC11159993/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20367638" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1111%2Fj.1349-7006.2010.01544.x" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Sci.&amp;title=Bortezomib+potentially+inhibits+cellular+growth+of+vascular+endothelial+cells+through+suppression+of+G2/M+transition&amp;author=D.+Tamura&amp;author=T.+Arao&amp;author=K.+Tanaka&amp;author=H.+Kaneda&amp;author=K.+Matsumoto&amp;volume=101&amp;publication_year=2010&amp;pages=1403-1408&amp;pmid=20367638&amp;doi=10.1111/j.1349-7006.2010.01544.x&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56-ijms-24-14646">56. <span class="element-citation">Caravita T., de Fabritiis P., Palumbo A., Amadori S., Boccadoro M. Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. <span><span class="ref-journal">Nat. Clin. Pract. Oncol. </span>2006;<span class="ref-vol">3</span>:374–387. doi: 10.1038/ncponc0555.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16826218" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1038%2Fncponc0555" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat.+Clin.+Pract.+Oncol.&amp;title=Bortezomib:+Efficacy+comparisons+in+solid+tumors+and+hematologic+malignancies&amp;author=T.+Caravita&amp;author=P.+de+Fabritiis&amp;author=A.+Palumbo&amp;author=S.+Amadori&amp;author=M.+Boccadoro&amp;volume=3&amp;publication_year=2006&amp;pages=374-387&amp;pmid=16826218&amp;doi=10.1038/ncponc0555&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57-ijms-24-14646">57. <span class="element-citation">Suares A., Mori Sequeiros Garcia M., Paz C., Gonzalez-Pardo V. Antiproliferative effects of Bortezomib in endothelial cells transformed by viral G protein-coupled receptor associated to Kaposi&#x02019;s sarcoma. <span><span class="ref-journal">Cell. Signal. </span>2017;<span class="ref-vol">32</span>:124–132. doi: 10.1016/j.cellsig.2017.01.025.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28161489" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.cellsig.2017.01.025" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell.+Signal.&amp;title=Antiproliferative+effects+of+Bortezomib+in+endothelial+cells+transformed+by+viral+G+protein-coupled+receptor+associated+to+Kaposi&#x02019;s+sarcoma&amp;author=A.+Suares&amp;author=M.+Mori+Sequeiros+Garcia&amp;author=C.+Paz&amp;author=V.+Gonzalez-Pardo&amp;volume=32&amp;publication_year=2017&amp;pages=124-132&amp;pmid=28161489&amp;doi=10.1016/j.cellsig.2017.01.025&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58-ijms-24-14646">58. <span class="element-citation">Kreis N.N., Louwen F., Yuan J. The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy. <span><span class="ref-journal">Cancers. </span>2019;<span class="ref-vol">11</span>:1220.  doi: 10.3390/cancers11091220.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC6770903/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31438587" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3390%2Fcancers11091220" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=The+Multifaceted+p21+(Cip1/Waf1/CDKN1A)+in+Cell+Differentiation,+Migration+and+Cancer+Therapy&amp;author=N.N.+Kreis&amp;author=F.+Louwen&amp;author=J.+Yuan&amp;volume=11&amp;publication_year=2019&amp;pages=1220&amp;pmid=31438587&amp;doi=10.3390/cancers11091220&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59-ijms-24-14646">59. <span class="element-citation">Cazzalini O., Scovassi A.I., Savio M., Stivala L.A., Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. <span><span class="ref-journal">Mutat. Res. </span>2010;<span class="ref-vol">704</span>:12–20. doi: 10.1016/j.mrrev.2010.01.009.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20096807" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1016%2Fj.mrrev.2010.01.009" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mutat.+Res.&amp;title=Multiple+roles+of+the+cell+cycle+inhibitor+p21(CDKN1A)+in+the+DNA+damage+response&amp;author=O.+Cazzalini&amp;author=A.I.+Scovassi&amp;author=M.+Savio&amp;author=L.A.+Stivala&amp;author=E.+Prosperi&amp;volume=704&amp;publication_year=2010&amp;pages=12-20&amp;pmid=20096807&amp;doi=10.1016/j.mrrev.2010.01.009&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60-ijms-24-14646">60. <span class="element-citation">Payne S.R., Zhang S., Tsuchiya K., Moser R., Gurley K.E., Longton G., deBoer J., Kemp C.J. p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability. <span><span class="ref-journal">Mol. Cell Biol. </span>2008;<span class="ref-vol">28</span>:258–268. doi: 10.1128/MCB.01536-07.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2223298/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17954563" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.1128%2FMCB.01536-07" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol.+Cell+Biol.&amp;title=p27kip1+deficiency+impairs+G2/M+arrest+in+response+to+DNA+damage,+leading+to+an+increase+in+genetic+instability&amp;author=S.R.+Payne&amp;author=S.+Zhang&amp;author=K.+Tsuchiya&amp;author=R.+Moser&amp;author=K.E.+Gurley&amp;volume=28&amp;publication_year=2008&amp;pages=258-268&amp;pmid=17954563&amp;doi=10.1128/MCB.01536-07&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61-ijms-24-14646">61. <span class="element-citation">Kobayashi D., Shibata A., Oike T., Nakano T. One-step Protocol for Evaluation of the Mode of Radiation-induced Clonogenic Cell Death by Fluorescence Microscopy. <span><span class="ref-journal">J. Vis. Exp. </span>2017;<span class="ref-vol">128</span>:e56338. doi: 10.3791/56338.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5755180/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29155723" ref="reftype=pubmed&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//doi.org/10.3791%2F56338" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J.+Vis.+Exp.&amp;title=One-step+Protocol+for+Evaluation+of+the+Mode+of+Radiation-induced+Clonogenic+Cell+Death+by+Fluorescence+Microscopy&amp;author=D.+Kobayashi&amp;author=A.+Shibata&amp;author=T.+Oike&amp;author=T.+Nakano&amp;volume=128&amp;publication_year=2017&amp;pages=e56338&amp;doi=10.3791/56338&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=10572992&amp;issue-id=447278&amp;journal-id=808&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">International Journal of Molecular Sciences</span> are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC10572992/pdf/ijms-24-14646.pdf" class="int-view">PDF (7.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/10572992/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/10572992/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="10572992" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="CPag1mvlYQBMPDtPt7MkxtNsuh2QMr5qxEkOJBgbS9ruqc8gO6hXFDPpIqiZm5F3">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F&amp;text=Bortezomib%20Is%20Effective%20in%20the%20Treatment%20of%20T%20Lymphoblastic%20Leukaemia%20by%20Inducing%20DNA%20Damage%2C%20WEE1%20Downregulation%2C%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC10572992%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572992/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/37834095/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/37834095/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC10572992/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/10572992/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC10572992/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
